



**Europäisches  
Patentamt**

**European  
Patent Office**

**Office européen  
des brevets**

**BEST AVAILABLE COPY**

REC'D 04 JUN 2004

WIPO

PCT

**Bescheinigung**

**Certificate**

**Attestation**

Die angehefteten Unterla-  
gen stimmen mit der  
ursprünglich eingereichten  
Fassung der auf dem näch-  
sten Blatt bezeichneten  
europäischen Patentanmel-  
dung überein.

The attached documents  
are exact copies of the  
European patent application  
described on the following  
page, as originally filed.

Les documents fixés à  
cette attestation sont  
conformes à la version  
initialement déposée de  
la demande de brevet  
européen spécifiée à la  
page suivante.

**Patentanmeldung Nr. Patent application No. Demande de brevet n°**

03006846.4

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

**R C van Dijk**



Anmeldung Nr:  
Application no.: 03006846.4  
Demande no:

Anmeldetag:  
Date of filing: 28.03.03  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Bayer Aktiengesellschaft

51368 Leverkusen  
ALLEMAGNE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se referer à la description.)

Diagnostics and Therapeutics for diseases associated with endothelial  
differentiation, sphingolipid G-Protein-coupled receptor 6 (EDG6)

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

G01N33/48

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of  
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL  
PT SE SI SK TR LI

**Diagnostics and Therapeutics for Diseases Associated with Endothelial Differentiation, Sphingolipid G-Protein-Coupled Receptor 6 (EDG6)**

5 **Technical field of the invention**

The present invention is in the field of molecular biology, more particularly, the present invention relates to nucleic acid sequences and amino acid sequences of a human EDG6 and its regulation for the treatment of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, 10 respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in mammals.

**Background of the invention**

15

**G-Protein Coupled Receptors**

EDG6 is a seven transmembrane G protein coupled receptor (GPCR) [Jedlicka et al. (1994), Graler et al. (1998), Yamazaki Y et al. (2000), WO 200206446, WO 200014233]. Many medically significant biological processes are mediated by signal transduction pathways that involve G-proteins [Lefkowitz, (1991)]. The family of G-protein coupled receptors (GPCRs) includes receptors for hormones, neurotransmitters, growth factors, and viruses. Specific examples of GPCRs include receptors for such diverse agents as dopamine, calcitonine, adrenergic hormones, 20 endotheline, cAMP, adenosine, acetylcholine, serotonin, histamine, thrombin, kinine, follicle stimulating hormone, opsins, endothelial differentiation gene-1, rhodopsins, odorants, cytomegalovirus, G-proteins themselves, effector proteins such as phospholipase C, adenylyl cyclase, and phosphodiesterase, and actuator proteins such as protein kinase A and protein kinase C.

30

GPCRs possess seven conserved membrane-spanning domains connecting at least eight divergent hydrophilic loops. GPCRs, also known as seven transmembrane, 7TM, receptors, have been characterized as including these seven conserved hydrophobic stretches of about 20 to 30 amino acids, connecting at least eight divergent hydrophilic loops. Most GPCRs have single conserved cysteine residues in each of the first two extracellular loops, which form disulfide bonds that are believed to stabilize functional protein structure. The seven transmembrane regions are designated as TM1, TM2, TM3, TM4, TM5, TM6, and TM7. TM3 is being implicated with signal transduction. Phosphorylation and lipidation (palmitoylation or farnesylation) of cysteine residues can influence signal transduction of some GPCRs. Most GPCRs contain potential phosphorylation sites within the third cytoplasmic loop and/or the carboxy terminus. For several GPCRs, such as the beta-adrenergic receptor, phosphorylation by protein kinase A and/or specific receptor kinases mediates receptor desensitization.

For some receptors, the ligand binding sites of GPCRs are believed to comprise hydrophilic sockets formed by several GPCR transmembrane domains. The hydrophilic sockets are surrounded by hydrophobic residues of the GPCRs. The hydrophilic side of each GPCR transmembrane helix is postulated to face inward and form a polar ligand binding site. TM3 is being implicated with several GPCRs as having a ligand binding site, such as the TM3 aspartate residue. TM5 serines, a TM6 asparagine, and TM6 or TM7 phenylalanines or tyrosines also are implicated in ligand binding.

GPCRs are coupled inside the cell by heterotrimeric G-proteins to various intracellular enzymes, ion channels, and transporters. Different G-protein alpha-subunits preferentially stimulate particular effectors to modulate various biological functions in a cell. Phosphorylation of cytoplasmic residues of GPCRs is an important mechanism for the regulation of some GPCRs. For example, in one form of signal transduction, the effect of hormone binding is the activation of the enzyme, adenylate cyclase, inside the cell. Enzyme activation by hormones is dependent on



the presence of the nucleotide GTP. GTP also influences hormone binding. A G-protein connects the hormone receptor to adenylate cyclase. G-protein exchanges GTP for bound GDP when activated by a hormone receptor. The GTP-carrying form then binds to activated adenylate cyclase. Hydrolysis of GTP to GDP, catalyzed by the G-protein itself, returns the G-protein to its basal, inactive form. Thus, the G-protein serves a dual rôle, as an intermediate that relays the signal from receptor to effector, and as a clock that controls the duration of the signal.

Over the past 15 years, nearly 350 therapeutic agents targeting 7TM receptors have been successfully introduced into the market. This indicates that these receptors have an established, proven history as therapeutic targets. Clearly, there is a need for identification and characterization of further receptors which can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, cancers, allergies including asthma, cardiovascular diseases including acute heart failure, hypotension, hypertension, angina pectoris, myocardial infarction, hematological diseases, genito-urinary diseases including urinary incontinence and benign prostate hyperplasia, osteoporosis, and peripheral and central nervous system disorders including pain, Alzheimer's disease and Parkinson's disease.

#### **TaqMan-Technology / expression profiling**

TaqMan is a recently developed technique, in which the release of a fluorescent reporter dye from a hybridisation probe in real-time during a polymerase chain reaction (PCR) is proportional to the accumulation of the PCR product. Quantification is based on the early, linear part of the reaction, and by determining the threshold cycle (CT), at which fluorescence above background is first detected.

Gene expression technologies may be useful in several areas of drug discovery and development, such as target identification, lead optimization, and identification of

mechanisms of action. The TaqMan technology can be used to compare differences between expression profiles of normal tissue and diseased tissue. Expression profiling has been used in identifying genes, which are up- or downregulated in a variety of diseases. An interesting application of expression profiling is temporal monitoring of changes in gene expression during disease progression and drug treatment or in patients versus healthy individuals. The premise in this approach is that changes in pattern of gene expression in response to physiological or environmental stimuli (e.g., drugs) may serve as indirect clues about disease-causing genes or drug targets. Moreover, the effects of drugs with established efficacy on global gene expression patterns may provide a guidepost, or a genetic signature, against which a new drug candidate can be compared.

### EDG6

The nucleotide sequence of EDG6 is accessible in public databases by the accession number NM\_003775 and is given in SEQ ID NO: 1. The amino acid sequence of EDG6 is depicted in SEQ ID NO: 2.

The lysolipid mediators lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) signal cells through a set of G protein-coupled receptors (GPCRs) known as EDG receptors. Some EDG receptors (e.g., EDG1) are S1P receptors; others (e.g., EDG2) are LPA receptors.

By PCR with degenerate oligonucleotides derived from regions conserved among GPCRs, Graler et al. (1998) cloned differentiated dendritic cell cDNAs encoding EDG6. The predicted 384-amino acid EDG6 protein has 7 transmembrane domains. The EDG6 protein shares 82% sequence identity with mouse Edg6, 46% identity with human EDG3, 44% identity with human EDG1, 39% identity with human EDG4, and 37% identity with human EDG2. Northern blot analysis indicated that EDG6 is expressed as a 1.7-kb transcript in fetal and adult lymphoid and hematopoietic tissues, lung, and Burkitt lymphoma cell lines.

5 Graler et al. (1998) noted that the 3-prime end of their EDG6 cDNA is identical to a short sequence encompassing the dinucleotide repeat polymorphism D19S120 (GenBank X65642), which was assigned to 19p13.3 by Jedlicka et al. (1994). By PCR of human genomic DNA using a gene-specific primer to EDG6 and a primer to the D19S120 amplicon, Graler et al. (1998) localized the EDG6 gene to 19p13.3.

10 Yamazaki Y et al. (2000) describe ligand binding studies for EDG6. Transfection of the Edg-6 into Chinese hamster ovary (CHO) cells and K562 cells resulted in the appearance of high-affinity [(3)H]S1P binding activity. Among lipids employed, S1P and, even though less potent, SPC, displaced the [(3)H]S1P binding, but LPA was inactive. In Edg-6-transfected CHO cells, an increase in cytosolic Ca(2+) concentration in response to S1P or SPC was clearly enhanced without change in the LPA-induced action as compared with the vector-transfected cells. The enhancement  
15 of the Ca(2+) response was associated with a significant accumulation of inositol phosphate, reflecting activation of phospholipase C. Similar enhancement of Ca(2+) response to S1P or SPC was also observed in Edg-6-expressing K562 cells. These lipid-induced actions in CHO cells and K562 cells expressing Edg-6 were markedly suppressed by pertussis toxin treatment. Yamazaki Y et al. (2000) conclude that Edg-  
20 6 is one of S1P or lysosphingolipid receptors that couple to phospholipase C-Ca(2+) system through pertussis toxin-sensitive G-proteins.

25 The receptor EDG6 is published in WO 200206446 and WO 200014233. EDG6 shows the highest homology (42 %) to the human receptor EDG3 receptor as shown in example 1.

### Summary of the invention

30 The invention relates to novel disease associations of EDG6 polypeptides and polynucleotides. The invention also relates to novel methods of screening for therapeutic agents for the treatment of cardiovascular disorders, gastrointestinal and

liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders in a mammal. The invention also relates to pharmaceutical compositions for the treatment of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders in a mammal comprising a EDG6 polypeptide, a EDG6 polynucleotide, or regulators of EDG6 or modulators of EDG6 activity. The invention further comprises methods of diagnosing cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders in a mammal.

Furthermore, the invention relates to novel methods of screening for therapeutic agents for the stimulation of thrombopoiesis and to novel methods of screening for therapeutic agents for the treatment of myeloma or thrombocytopenia. Platelets are fragmented particles derived from the cytosolic extensions of mature megakaryocytes. We show that the development of megakaryocytes from progenitor cells is regulated by the lysophospholipid sphingosine-1-phosphate (S1P) and is correlated with the expression of a distinct set of S1P receptors. Among the S1P receptors, S1P<sub>4</sub> (EDG6) promoted endomitosis, process formation, and subsequent release of platelet-like particles from transfected HEL cells. The process formation was associated with the down regulation of Rho and the activation of Cdc42 small guanosine triphosphatases (GTPases). This regulation may have important implications in diseases such as Wiskott-Aldrich Syndrome where the disruption of the Cdc42 to WASP signaling pathway may explain the resultant thrombocytopenia observed in patients with the WASP mutation. These data strongly support the notion that EDG6 is a key molecule regulating megakaryocytopoiesis and platelet production. Therefore, an agonist of EDG6 may be useful for stimulating thrombopoiesis. Conversely, an antagonist of EDG6 may be useful for treating certain types of myeloma. Thus, the invention also relates to pharmaceutical compositions for the stimulation of thrombopoiesis or the treatment of myeloma in a mammal comprising a EDG6 polypeptide, a EDG6 polynucleotide, or regulators of EDG6 or modulators of

EDG6 activity. The invention further comprises methods of diagnosing thrombocytopenia or myeloma.

Furthermore, these data support the fact, that modulators of EDG6 activity may be  
5 useful for treating immunological disorders such as autoimmunity, inflammation and  
transplantation. It is particularly interesting to mention, that it is believed that a  
significant amount (30 % or so) of platelets is produced in the lung. And BALF from  
asthmatics contains elevated levels of S1P. Thus we think that a dysregulation of  
platelets in the lung may be involved in the pathology of pulmonary disorders such as  
10 asthma and COPD. Thus these findings also strongly support, that modulators of  
EDG6 activity may be useful for treating respiratory diseases as well.

**Brief Description of the Drawings**

15 Fig. 1 shows the nucleotide sequence of a EDG6 receptor polynucleotide (SEQ ID  
NO: 1).

Fig. 2 shows the amino acid sequence of a EDG6 receptor polypeptide (SEQ ID  
NO: 2).

20

Fig. 3 shows the nucleotide sequence of a primer useful for the invention (SEQ ID  
NO: 3).

Fig. 4 shows the nucleotide sequence of a primer useful for the invention (SEQ ID  
25 NO: 4).

Fig. 5 shows a nucleotide sequence useful as a probe to detect proteins of the  
invention (SEQ ID NO: 5).

30 Fig. 6 shows S1P effects on megakaryocyte development.

- 5 (A) CD34<sup>+</sup> cells from cord blood (upper panels) or bone marrow (lower panels) were subjected to the megakaryocyte colony formation assay with or without 10  $\mu$ M of S1P. Mean colony number per well of CD41 positive (CFU-MK) and negative (non-MK) colonies are plotted with SD (n=4 to 8, left panels). Significantly lower % CFU-MK (by *Student's t-test*) was obtained by S1P treatment in either experiment (right panels). The experiment was repeated twice with each progenitor and obtained similar results. #
- 10 (B) Megakaryocyte differentiation was induced for 12 days from the CD34<sup>+</sup> progenitor cells and the cells were separated for CD41 expression. RNAs from non-differentiated cells (Day 0), differentiated cells (Day 12), and peripheral platelets were analyzed for expression of S1P receptors by RT-PCR. Expression of  $\alpha_2$ -microglobulin is
- 15 shown as an internal control.

20 Fig. 7 shows S1P<sub>4</sub>-mediated HEL differentiation to megakaryocyte-like cells. PMA treatment at 10 nM for 72 hours induced large adherent cells in HEL and HEL/S1P<sub>4</sub>. Small particles (arrowhead) and a particle about to bud off from the cytosolic extension (arrow) are seen in HEL/S1P<sub>4</sub> treated with PMA.

25 Fig. 8 shows a scheme of a signaling model from S1P to megakaryocyte process formation. S1P<sub>4</sub> signal preferentially cascades to Rac and Cdc42 pathways that promote lamellipodia and filopodia formation, respectively, thereby may facilitate extension of cytosol without moving the cell body (note Rho is down-regulated). WASP mediates signals from Cdc42. Impairment of WASP, thus may cause reduction of platelet formation in patients.

## **Detailed description of the invention**

### **Definition of terms**

5 An "oligonucleotide" is a stretch of nucleotide residues which has a sufficient number of bases to be used as an oligomer, amplimer or probe in a polymerase chain reaction (PCR). Oligonucleotides are prepared from genomic or cDNA sequence and are used to amplify, reveal, or confirm the presence of a similar DNA or RNA in a particular cell or tissue. Oligonucleotides or oligomers comprise portions of a DNA  
10 sequence having at least about 10 nucleotides and as many as about 35 nucleotides, preferably about 25 nucleotides.

"Probes" may be derived from naturally occurring or recombinant single- or double-stranded nucleic acids or may be chemically synthesized. They are useful in  
15 detecting the presence of identical or similar sequences. Such probes may be labeled with reporter molecules using nick translation, Klenow fill-in reaction, PCR or other methods well known in the art. Nucleic acid probes may be used in southern, northern or in situ hybridizations to determine whether DNA or RNA encoding a certain protein is present in a cell type, tissue, or organ.

20 A "fragment of a polynucleotide" is a nucleic acid that comprises all or any part of a given nucleotide molecule, the fragment having fewer nucleotides than about 6 kb, preferably fewer than about 1 kb.

25 "Reporter molecules" are radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents which associate with a particular nucleotide or amino acid sequence, thereby establishing the presence of a certain sequence, or allowing for the quantification of a certain sequence.

30 "Chimeric" molecules may be constructed by introducing all or part of the nucleotide sequence of this invention into a vector containing additional nucleic acid sequence

which might be expected to change any one or several of the following EDG6 characteristics: cellular location, distribution, ligand-binding affinities, interchain affinities, degradation/turnover rate, signaling, etc.

5     "Active", with respect to a EDG6 polypeptide, refers to those forms, fragments, or domains of a EDG6 polypeptide which retain the biological and/or antigenic activity of a EDG6 polypeptide.

10    "Naturally occurring EDG6 polypeptide" refers to a polypeptide produced by cells which have not been genetically engineered and specifically contemplates various polypeptides arising from post-translational modifications of the polypeptide including but not limited to acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation.

15    "Derivative" refers to polypeptides which have been chemically modified by techniques such as ubiquitination, labeling (see above), pegylation (derivatization with polyethylene glycol), and chemical insertion or substitution of amino acids such as ornithine which do not normally occur in human proteins.

20    "Conservative amino acid substitutions" result from replacing one amino acid with another having similar structural and/or chemical properties, such as the replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine.

25    "Insertions" or "deletions" are typically in the range of about 1 to 5 amino acids. The variation allowed may be experimentally determined by producing the peptide synthetically while systematically making insertions, deletions, or substitutions of nucleotides in the sequence using recombinant DNA techniques.

30    A "signal sequence" or "leader sequence" can be used, when desired, to direct the polypeptide through a membrane of a cell. Such a sequence may be naturally present.



on the polypeptides of the present invention or provided from heterologous sources by recombinant DNA techniques.

5 An "oligopeptide" is a short stretch of amino acid residues and may be expressed from an oligonucleotide. Oligopeptides comprise a stretch of amino acid residues of at least 3, 5, 10 amino acids and at most 10, 15, 25 amino acids, typically of at least 9 to 13 amino acids, and of sufficient length to display biological and/or antigenic activity.

10 "Inhibitor" is any substance which retards or prevents a chemical or physiological reaction or response. Common inhibitors include but are not limited to antisense molecules, antibodies, and antagonists.

15 "Standard expression" is a quantitative or qualitative measurement for comparison. It is based on a statistically appropriate number of normal samples and is created to use as a basis of comparison when performing diagnostic assays, running clinical trials, or following patient treatment profiles.

20 "Animal" as used herein may be defined to include human, domestic (e.g., cats, dogs, etc.), agricultural (e.g., cows, horses, sheep, etc.) or test species (e.g., mouse, rat, rabbit, etc.).

A "EDG6 polynucleotide", within the meaning of the invention, shall be understood as being a nucleic acid molecule selected from a group consisting of

- 25
- (i) nucleic acid molecules encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 2,
  - (ii) nucleic acid molecules comprising the sequence of SEQ ID NO: 1,
  - 30 (iii) nucleic acid molecules having the sequence of SEQ ID NO: 1,

(iv) nucleic acid molecules the complementary strand of which hybridizes under stringent conditions to a nucleic acid molecule of (i), (ii), or (iii); and

5 (v) nucleic acid molecules the sequence of which differs from the sequence of a nucleic acid molecule of (iii) due to the degeneracy of the genetic code;

wherein the polypeptide encoded by said nucleic acid molecule has EDG6 activity.

10 A "EDG6 polypeptide", within the meaning of the invention, shall be understood as being a polypeptide selected from a group consisting of

(i) polypeptides having the sequence of SEQ ID NO: 2,

15 (ii) polypeptides comprising the sequence of SEQ ID NO: 2,

(iii) polypeptides encoded by EDG6 polynucleotides; and

(iv) polypeptides which show at least 99%, 98%, 95%, 90%, or 80% homology  
20 with a polypeptide of (i), (ii), or (iii);

wherein said polypeptide has EDG6 activity.

The nucleotide sequences encoding a EDG6 (or their complement) have numerous  
25 applications in techniques known to those skilled in the art of molecular biology. These techniques include use as hybridization probes, use in the construction of oligomers for PCR, use for chromosome and gene mapping, use in the recombinant production of EDG6, and use in generation of antisense DNA or RNA, their chemical analogs and the like. Uses of nucleotides encoding a EDG6 disclosed herein are  
30 exemplary of known techniques and are not intended to limit their use in any technique known to a person of ordinary skill in the art. Furthermore, the nucleotide

sequences disclosed herein may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, e.g., the triplet genetic code, specific base pair interactions, etc.

5

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of EDG6 - encoding nucleotide sequences may be produced. Some of these will only bear minimal homology to the nucleotide sequence of the known and naturally occurring EDG6. The invention has specifically contemplated each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring EDG6, and all such variations are to be considered as being specifically disclosed.

15

Although the nucleotide sequences which encode a EDG6, its derivatives or its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring EDG6 polynucleotide under stringent conditions, it may be advantageous to produce nucleotide sequences encoding EDG6 polypeptides or its derivatives possessing a substantially different codon usage. Codons can be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic expression host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding a EDG6 polypeptide and/or its derivatives without altering the encoded amino acid sequence include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

25

Nucleotide sequences encoding a EDG6 polypeptide may be joined to a variety of other nucleotide sequences by means of well established recombinant DNA techniques. Useful nucleotide sequences for joining to EDG6 polynucleotides

30

include an assortment of cloning vectors such as plasmids, cosmids, lambda phage derivatives, phagemids, and the like. Vectors of interest include expression vectors, replication vectors, probe generation vectors, sequencing vectors, etc. In general, vectors of interest may contain an origin of replication functional in at least one organism, convenient restriction endonuclease sensitive sites, and selectable markers for one or more host cell systems.

Another aspect of the subject invention is to provide for EDG6-specific hybridization probes capable of hybridizing with naturally occurring nucleotide sequences encoding EDG6. Such probes may also be used for the detection of similar GPCR encoding sequences and should preferably show at least 40% nucleotide identity to EDG6 polynucleotides. The hybridization probes of the subject invention may be derived from the nucleotide sequence presented as SEQ ID NO: 1 or from genomic sequences including promoter, enhancers or introns of the native gene. Hybridization probes may be labelled by a variety of reporter molecules using techniques well known in the art.

It will be recognized that many deletional or mutational analogs of EDG6 polynucleotides will be effective hybridization probes for EDG6 polynucleotides. Accordingly, the invention relates to nucleic acid sequences that hybridize with such EDG6 encoding nucleic acid sequences under stringent conditions.

"Stringent conditions" refers to conditions that allow for the hybridization of substantially related nucleic acid sequences. For instance, such conditions will generally allow hybridization of sequence with at least about 85% sequence identity, preferably with at least about 90% sequence identity, more preferably with at least about 95% sequence identity. Hybridization conditions and probes can be adjusted in well-characterized ways to achieve selective hybridization of human-derived probes. Stringent conditions, within the meaning of the invention are 65°C in a buffer containing 1 mM EDTA, 0.5 M NaHPO<sub>4</sub> (pH 7.2), 7 % (w/v) SDS.

Nucleic acid molecules that will hybridize to EDG6 polynucleotides under stringent conditions can be identified functionally. Without limitation, examples of the uses for hybridization probes include: histochemical uses such as identifying tissues that express EDG6; measuring mRNA levels, for instance to identify a sample's tissue type or to identify cells that express abnormal levels of EDG6; and detecting polymorphisms of EDG6.

PCR provides additional uses for oligonucleotides based upon the nucleotide sequence which encodes EDG6. Such probes used in PCR may be of recombinant origin, chemically synthesized, or a mixture of both. Oligomers may comprise discrete nucleotide sequences employed under optimized conditions for identification of EDG6 in specific tissues or diagnostic use. The same two oligomers, a nested set of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for identification of closely related DNAs or RNAs.

Rules for designing polymerase chain reaction (PCR) primers are now established, as reviewed by PCR Protocols. Degenerate primers, i.e., preparations of primers that are heterogeneous at given sequence locations, can be designed to amplify nucleic acid sequences that are highly homologous to, but not identical with EDG6. Strategies are now available that allow for only one of the primers to be required to specifically hybridize with a known sequence. For example, appropriate nucleic acid primers can be ligated to the nucleic acid sought to be amplified to provide the hybridization partner for one of the primers. In this way, only one of the primers need be based on the sequence of the nucleic acid sought to be amplified.

PCR methods for amplifying nucleic acid will utilize at least two primers. One of these primers will be capable of hybridizing to a first strand of the nucleic acid to be amplified and of priming enzyme-driven nucleic acid synthesis in a first direction. The other will be capable of hybridizing the reciprocal sequence of the first strand (if the sequence to be amplified is single stranded, this sequence will initially be hypothetical, but will be synthesized in the first amplification cycle) and of priming

nucleic acid synthesis from that strand in the direction opposite the first direction and towards the site of hybridization for the first primer. Conditions for conducting such amplifications, particularly under preferred stringent hybridization conditions, are well known.

5 Other means of producing specific hybridization probes for EDG6 include the cloning of nucleic acid sequences encoding EDG6 or EDG6 derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available and may be used to synthesize RNA probes in vitro by means  
10 of the addition of the appropriate RNA polymerase as T7 or SP6 RNA polymerase and the appropriate reporter molecules.

It is possible to produce a DNA sequence, or portions thereof, entirely by synthetic chemistry. After synthesis, the nucleic acid sequence can be inserted into any of the  
15 many available DNA vectors and their respective host cells using techniques which are well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into the nucleotide sequence. Alternately, a portion of sequence in which a mutation is desired can be synthesized and recombined with longer portion of an existing genomic or recombinant sequence.

20 EDG6 polynucleotides may be used to produce a purified oligo-or polypeptide using well known methods of recombinant DNA technology. The oligopeptide may be expressed in a variety of host cells, either prokaryotic or eukaryotic. Host cells may be from the same species from which the nucleotide sequence was derived or from a  
25 different species. Advantages of producing an oligonucleotide by recombinant DNA technology include obtaining adequate amounts of the protein for purification and the availability of simplified purification procedures.

### Quantitative determinations of nucleic acids

5 An important step in the molecular genetic analysis of human disease is often the enumeration of the copy number of a nucleic acid or the relative expression of a gene in particular tissues.

10 Several different approaches are currently available to make quantitative determinations of nucleic acids. Chromosome-based techniques, such as comparative genomic hybridization (CGH) and fluorescent in situ hybridization (FISH) facilitate efforts to cytogenetically localize genomic regions that are altered in tumor cells. Regions of genomic alteration can be narrowed further using loss of heterozygosity analysis (LOH), in which disease DNA is analyzed and compared with normal DNA for the loss of a heterozygous polymorphic marker. The first experiments used restriction fragment length polymorphisms (RFLPs) [Johnson, (1989)], or hyper-  
15 variable minisatellite DNA [Barnes, 2000]. In recent years LOH has been performed primarily using PCR amplification of microsatellite markers and electrophoresis of the radio labelled [Jeffreys, (1985)] or fluorescently labelled PCR products [Weber, (1990)] and compared between paired normal and disease DNAs.

20 A number of other methods have also been developed to quantify nucleic acids [Gergen, (1992)]. More recently, PCR and RT-PCR methods have been developed which are capable of measuring the amount of a nucleic acid in a sample. One approach, for example, measures PCR product quantity in the log phase of the reaction before the formation of reaction products plateaus [Thomas, (1980)].

25 A gene sequence contained in all samples at relatively constant quantity is typically utilized for sample amplification efficiency normalization. This approach, however, suffers from several drawbacks. The method requires that each sample has equal input amounts of the nucleic acid and that the amplification efficiency between  
30 samples is identical until the time of analysis. Furthermore, it is difficult using the conventional methods of PCR quantitation such as gel electrophoresis or plate

capture hybridization to determine that all samples are in fact analyzed during the log phase of the reaction as required by the method.

5 Another method called quantitative competitive (QC)-PCR, as the name implies, relies on the inclusion of an internal control competitor in each reaction [Piatak, (1993), BioTechniques]. The efficiency of each reaction is normalized to the internal competitor. A known amount of internal competitor is typically added to each sample. The unknown target PCR product is compared with the known competitor PCR product to obtain relative quantitation. A difficulty with this general approach  
10 lies in developing an internal control that amplifies with the same efficiency than the target molecule.

#### *5' Fluorogenic Nuclease Assays*

15 Fluorogenic nuclease assays are a real time quantitation method that uses a probe to monitor formation of amplification product. The basis for this method of monitoring the formation of amplification product is to measure continuously PCR product accumulation using a dual-labelled fluorogenic oligonucleotide probe, an approach frequently referred to in the literature simply as the "TaqMan method" [Piatak,  
20 (1993), Science; Heid, (1996); Gibson, (1996); Holland. (1991)].

The probe used in such assays is typically a short (about 20-25 bases) oligonucleotide that is labeled with two different fluorescent dyes. The 5' terminus of the probe is attached to a reporter dye and the 3' terminus is attached to a quenching dye,  
25 although the dyes could be attached at other locations on the probe as well. The probe is designed to have at least substantial sequence complementarity with the probe binding site. Upstream and downstream PCR primers which bind to flanking regions of the locus are added to the reaction mixture. When the probe is intact, energy transfer between the two fluorophors occurs and the quencher quenches  
30 emission from the reporter. During the extension phase of PCR, the probe is cleaved by the 5' nuclease activity of a nucleic acid polymerase such as Taq polymerase,



thereby releasing the reporter from the oligonucleotide-quencher and resulting in an increase of reporter emission intensity which can be measured by an appropriate detector.

5 One detector which is specifically adapted for measuring fluorescence emissions such as those created during a fluorogenic assay is the ABI 7700 or 4700 HT manufactured by Applied Biosystems, Inc. in Foster City, Calif. The ABI 7700 uses fiber optics connected with each well in a 96-or 384 well PCR tube arrangement. The instrument includes a laser for exciting the labels and is capable of measuring  
10 the fluorescence spectra intensity from each tube with continuous monitoring during PCR amplification. Each tube is re-examined every 8.5 seconds.

Computer software provided with the instrument is capable of recording the fluorescence intensity of reporter and quencher over the course of the amplification.  
15 The recorded values will then be used to calculate the increase in normalized reporter emission intensity on a continuous basis. The increase in emission intensity is plotted versus time, i.e., the number of amplification cycles, to produce a continuous measure of amplification. To quantify the locus in each amplification reaction, the amplification plot is examined at a point during the log phase of product  
20 accumulation. This is accomplished by assigning a fluorescence threshold intensity above background and determining the point at which each amplification plot crosses the threshold (defined as the threshold cycle number or Ct). Differences in threshold cycle number are used to quantify the relative amount of PCR target contained within each tube. Assuming that each reaction functions at 100% PCR efficiency, a  
25 difference of one Ct represents a two-fold difference in the amount of starting template. The fluorescence value can be used in conjunction with a standard curve to determine the amount of amplification product present.

*Non-Probe-Based Detection Methods*

A variety of options are available for measuring the amplification products as they are formed. One method utilizes labels, such as dyes, which only bind to double stranded DNA. In this type of approach, amplification product (which is double stranded) binds dye molecules in solution to form a complex. With the appropriate dyes, it is possible to distinguish between dye molecules free in solution and dye molecules bound to amplification product. For example, certain dyes fluoresce only when bound to amplification product. Examples of dyes which can be used in methods of this general type include, but are not limited to, Syber Green.TM. and Pico Green from Molecular Probes, Inc. of Eugene, Oreg., ethidium bromide, propidium iodide, chromomycin, acridine orange, Hoechst 33258, Toto-1, Yoyo-1, DAPI (4',6-diamidino-2-phenylindole hydrochloride).

Another real time detection technique measures alteration in energy fluorescence energy transfer between fluorophors conjugated with PCR primers [Livak, (1995)]:

*Probe-Based Detection Methods*

These detection methods involve some alteration to the structure or conformation of a probe hybridized to the locus between the amplification primer pair. In some instances, the alteration is caused by the template-dependent extension catalyzed by a nucleic acid polymerase during the amplification process. The alteration generates a detectable signal which is an indirect measure of the amount of amplification product formed.

For example, some methods involve the degradation or digestion of the probe during the extension reaction. These methods are a consequence of the 5'-3' nuclease activity associated with some nucleic acid polymerases. Polymerases having this activity cleave mononucleotides or small oligonucleotides from an oligonucleotide probe annealed to its complementary sequence located within the locus.

5 The 3' end of the upstream primer provides the initial binding site for the nucleic acid polymerase. As the polymerase catalyzes extension of the upstream primer and encounters the bound probe, the nucleic acid polymerase displaces a portion of the 5' end of the probe and through its nuclease activity cleaves mononucleotides or oligonucleotides from the probe.

10 The upstream primer and the probe can be designed such that they anneal to the complementary strand in close proximity to one another. In fact, the 3' end of the upstream primer and the 5' end of the probe may abut one another. In this situation, extension of the upstream primer is not necessary in order for the nucleic acid polymerase to begin cleaving the probe. In the case in which intervening nucleotides separate the upstream primer and the probe, extension of the primer is necessary before the nucleic acid polymerase encounters the 5' end of the probe. Once contact occurs and polymerization continues, the 5'-3' exonuclease activity of the nucleic acid polymerase begins cleaving mononucleotides or oligonucleotides from the 5' end of the probe. Digestion of the probe continues until the remaining portion of the probe dissociates from the complementary strand.

20 In solution, the two end sections can hybridize with each other to form a hairpin loop. In this conformation, the reporter and quencher dye are in sufficiently close proximity that fluorescence from the reporter dye is effectively quenched by the quencher dye. Hybridized probe, in contrast, results in a linearized conformation in which the extent of quenching is decreased. Thus, by monitoring emission changes for the two dyes, it is possible to indirectly monitor the formation of amplification product.

### *Probes*

30 The labeled probe is selected so that its sequence is substantially complementary to a segment of the test locus or a reference locus. As indicated above, the nucleic acid

site to which the probe binds should be located between the primer binding sites for the upstream and downstream amplification primers.

### *Primers*

5

The primers used in the amplification are selected so as to be capable of hybridizing to sequences at flanking regions of the locus being amplified. The primers are chosen to have at least substantial complementarity with the different strands of the nucleic acid being amplified. When a probe is utilized to detect the formation of amplification products, the primers are selected in such that they flank the probe, i.e. are located upstream and downstream of the probe.

10

The primer must have sufficient length so that it is capable of priming the synthesis of extension products in the presence of an agent for polymerization. The length and composition of the primer depends on many parameters, including, for example, the temperature at which the annealing reaction is conducted, proximity of the probe binding site to that of the primer, relative concentrations of the primer and probe and the particular nucleic acid composition of the probe. Typically the primer includes 15-30 nucleotides. However, the length of the primer may be more or less depending on the complexity of the primer binding site and the factors listed above.

15

20

### *Labels for Probes and Primers*

The labels used for labeling the probes or primers of the current invention and which can provide the signal corresponding to the quantity of amplification product can take a variety of forms. As indicated above with regard to the 5' fluorogenic nuclease method, a fluorescent signal is one signal which can be measured. However, measurements may also be made, for example, by monitoring radioactivity, colorimetry, absorption, magnetic parameters, or enzymatic activity. Thus, labels which can be employed include, but are not limited to, fluorophores, chromophores,

25

30

radioactive isotopes, electron dense reagents, enzymes, and ligands having specific binding partners (e.g., biotin-avidin).

5 Monitoring changes in fluorescence is a particularly useful way to monitor the accumulation of amplification products. A number of labels useful for attachment to probes or primers are commercially available including fluorescein and various fluorescein derivatives such as FAM, HEX, TET and JOE (all which are available from Applied Biosystems, Foster City, Calif.); lucifer yellow, and coumarin derivatives.

10

Labels may be attached to the probe or primer using a variety of techniques and can be attached at the 5' end, and/or the 3' end and/or at an internal nucleotide. The label can also be attached to spacer arms of various sizes which are attached to the probe or primer. These spacer arms are useful for obtaining a desired distance between multiple labels attached to the probe or primer.

15

In some instances, a single label may be utilized; whereas, in other instances, such as with the 5' fluorogenic nuclease assays for example, two or more labels are attached to the probe. In cases wherein the probe includes multiple labels, it is generally advisable to maintain spacing between the labels which is sufficient to permit separation of the labels during digestion of the probe through the 5'-3' nuclease activity of the nucleic acid polymerase.

20

#### **Patients Exhibiting Symptoms of Disease**

25

A number of diseases are associated with changes in the copy number of a certain gene. For patients having symptoms of a disease, the real-time PCR method can be used to determine if the patient has copy number alterations which are known to be linked with diseases that are associated with the symptoms the patient has.

30

**EDG6 expression***EDG6 fusion proteins*

5 Fusion proteins are useful for generating antibodies against EDG6 polypeptides and for use in various assay systems. For example, fusion proteins can be used to identify proteins which interact with portions of EDG6 polypeptides. Protein affinity chromatography or library-based assays for protein-protein interactions, such as the yeast two-hybrid or phage display systems, can be used for this purpose. Such  
10 methods are well known in the art and also can be used as drug screens.

A EDG6 fusion protein comprises two polypeptide segments fused together by means of a peptide bond. The first polypeptide segment can comprise at least 54, 75, 100, 125, 139, 150, 175, 200, 225, 250, or 275 contiguous amino acids of SEQ ID  
15 NO: 2 or of a biologically active variant, such as those described above. The first polypeptide segment also can comprise full-length EDG6.

The second polypeptide segment can be a full-length protein or a protein fragment. Proteins commonly used in fusion protein construction include, but are not limited to  
20  $\beta$ -galactosidase,  $\beta$ -glucuronidase, green fluorescent protein (GFP), autofluorescent proteins, including blue fluorescent protein (BFP), glutathione-S-transferase (GST), luciferase, horseradish peroxidase (HRP), and chloramphenicol acetyltransferase (CAT). Additionally, epitope tags are used in fusion protein constructions, including  
25 histidine (His) tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Other fusion constructions can include maltose binding protein (MBP), S-tag, Lex a DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, herpes simplex virus (HSV) BP16 protein fusions and G-protein fusions (for example G(alpha)16, Gs, Gi). A fusion protein also can be engineered to contain a cleavage site located adjacent to the EDG6.

### *Preparation of Polynucleotides*

A naturally occurring EDG6 polynucleotide can be isolated free of other cellular components such as membrane components, proteins, and lipids. Polynucleotides can be made by a cell and isolated using standard nucleic acid purification techniques, or synthesized using an amplification technique, such as the polymerase chain reaction (PCR), or by using an automatic synthesizer. Methods for isolating polynucleotides are routine and are known in the art. Any such technique for obtaining a polynucleotide can be used to obtain isolated EDG6 polynucleotides. For example, restriction enzymes and probes can be used to isolate polynucleotide fragments which comprise EDG6 nucleotide sequences. Isolated polynucleotides are in preparations which are free or at least 70, 80, or 90% free of other molecules.

EDG6 cDNA molecules can be made with standard molecular biology techniques, using EDG6 mRNA as a template. EDG6 cDNA molecules can thereafter be replicated using molecular biology techniques known in the art. An amplification technique, such as PCR, can be used to obtain additional copies of polynucleotides of the invention, using either human genomic DNA or cDNA as a template.

Alternatively, synthetic chemistry techniques can be used to synthesize EDG6 polynucleotides. The degeneracy of the genetic code allows alternate nucleotide sequences to be synthesized which will encode EDG6 having, for example, an amino acid sequence shown in SEQ ID NO: 2 or a biologically active variant thereof.

### *Extending Polynucleotides*

Various PCR-based methods can be used to extend nucleic acid sequences encoding human EDG6, for example to detect upstream sequences of EDG6 gene such as promoters and regulatory elements. For example, restriction-site PCR uses universal primers to retrieve unknown sequence adjacent to a known locus. Genomic DNA is first amplified in the presence of a primer to a linker sequence and a primer specific

to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

5

Inverse PCR also can be used to amplify or extend sequences using divergent primers based on a known region. Primers can be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, Minn.), to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68-72°C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

10

15

Another method which can be used is capture PCR, which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA. In this method, multiple restriction enzyme digestions and ligations also can be used to place an engineered double-stranded sequence into an unknown fragment of the DNA molecule before performing PCR.

20

25

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Randomly-primed libraries are preferable, in that they will contain more sequences which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries can be useful for extension of sequence into 5' non-transcribed regulatory regions.

30

Commercially available capillary electrophoresis systems can be used to analyze the size or confirm the nucleotide sequence of PCR or sequencing products. For example, capillary sequencing can employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser



activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity can be converted to electrical signal using appropriate equipment and software (e.g., GENOTYPER and Sequence NAVIGATOR, Perkin Elmer), and the entire process from loading of samples to computer analysis and electronic data display can be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.

#### *Obtaining Polypeptides*

EDG6 can be obtained, for example, by purification from human cells, by expression of EDG6 polynucleotides, or by direct chemical synthesis.

#### *Protein Purification*

EDG6 can be purified from any human cell which expresses the receptor; including those which have been transfected with expression constructs which express EDG6. A purified EDG6 is separated from other compounds which normally associate with EDG6 in the cell, such as certain proteins, carbohydrates, or lipids, using methods well-known in the art. Such methods include, but are not limited to, size exclusion chromatography, ammonium sulfate fractionation, ion exchange chromatography, affinity chromatography, and preparative gel electrophoresis.

#### *Expression of EDG6 Polynucleotides*

To express EDG6, EDG6 polynucleotides can be inserted into an expression vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. Methods which are well known to those skilled in the art can be used to construct expression vectors containing sequences encoding EDG6 and appropriate transcriptional and translational control elements. These methods

include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination.

5 A variety of expression vector/host systems can be utilized to contain and express sequences encoding EDG6. These include, but are not limited to, microorganisms, such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors, insect cell systems infected with virus expression vectors (e.g., baculovirus), plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids), or animal cell systems.

15 The control elements or regulatory sequences are those non-translated regions of the vector - enhancers, promoters, 5' and 3' untranslated regions -- which interact with host cellular proteins to carry out transcription and translation. Such elements can vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, can be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene, LaJolla, Calif.) or pSPORT1 plasmid (Life Technologies) and the like can be used. The baculovirus polyhedrin promoter can be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO, and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) can be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of a nucleotide sequence encoding EDG6, vectors based on SV40 or EBV can be used with an appropriate selectable marker.

### *Bacterial and Yeast Expression Systems*

In bacterial systems, a number of expression vectors can be selected. For example, when a large quantity of EDG6 is needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified can be used. Such vectors include, but are not limited to, multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene). In a BLUESCRIPT vector, a sequence encoding EDG6 can be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of  $\beta$ -galactosidase so that a hybrid protein is produced. pIN vectors or pGEX vectors (Promega, Madison, Wis.) also can be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems can be designed to include heparin, thrombin, or factor Xa protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

### *Plant and Insect Expression Systems*

If plant expression vectors are used, the expression of sequences encoding EDG6 can be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV can be used alone or in combination with the omega leader sequence from TMV. Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters can be used. These constructs can be introduced into plant cells by direct DNA transformation or by pathogen-mediated transfection.

An insect system also can be used to express EDG6. For example, in one such system *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia*

larvae. Sequences encoding EDG6 can be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of EDG6 will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses can then be used to infect *S. frugiperda* cells or *Trichoplusia* larvae in which EDG6 can be expressed.

### *Mammalian Expression Systems*

A number of viral-based expression systems can be used to express EDG6 in mammalian host cells. For example, if an adenovirus is used as an expression vector, sequences encoding EDG6 can be ligated into an adenovirus transcription/translation complex comprising the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome can be used to obtain a viable virus which is capable of expressing EDG6 in infected host cells [Engelhard, 1994]]. If desired, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, can be used to increase expression in mammalian host cells.

Human artificial chromosomes (HACs) also can be used to deliver larger fragments of DNA than can be contained and expressed in a plasmid. HACs of 6M to 10M are constructed and delivered to cells via conventional delivery methods (e.g., liposomes, polycationic amino polymers, or vesicles). Specific initiation signals also can be used to achieve more efficient translation of sequences encoding EDG6. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding EDG6, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals (including the ATG initiation codon) should be provided. The initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous

translational elements and initiation codons can be of various origins, both natural and synthetic.

### *Host Cells*

5 A host cell strain can be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed EDG6 in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-  
10 translational processing which cleaves a "prepro" form of the polypeptide also can be used to facilitate correct insertion, folding and/or function. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC; 10801 University Boulevard, Manassas,  
15 VA 20110-2209) and can be chosen to ensure the correct modification and processing of the foreign protein.

Stable expression is preferred for long-term, high-yield production of recombinant proteins. For example, cell lines which stably express EDG6 can be transformed  
20 using expression vectors which can contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells can be allowed to grow for 1-2 days in an enriched medium before they are switched to a selective medium. The purpose of the selectable marker is to confer resistance to selection,  
25 and its presence allows growth and recovery of cells which successfully express the introduced EDG6 sequences. Resistant clones of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type. Any number of selection systems can be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase [Logan, (1984)] and adenine phosphoribosyltransferase [Wigler, (1977)] genes which can be employed in  
30 *tk* or *aprt* cells, respectively. Also, antimetabolite, antibiotic, or herbicide resistance

can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate [Lowy, (1980)], *npt* confers resistance to the aminoglycosides, neomycin and G-418 [Wigler, (1980)], and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively [Colbere-Garapin, 1981]. Additional selectable genes have been described. For example, *trpB* allows cells to utilize indole in place of tryptophan, or *hisD*, which allows cells to utilize histinol in place of histidine. Visible markers such as anthocyanins,  $\beta$ -glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, can be used to identify transformants and to quantify the amount of transient or stable protein expression attributable to a specific vector system

#### *Detecting Polypeptide Expression*

Although the presence of marker gene expression suggests that a EDG6 polynucleotide is also present, its presence and expression may need to be confirmed. For example, if a sequence encoding EDG6 is inserted within a marker gene sequence, transformed cells containing sequences which encode EDG6 can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding EDG6 under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of EDG6 polynucleotide.

Alternatively, host cells which contain a EDG6 polynucleotide and which express EDG6 can be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip-based technologies for the detection and/or quantification of nucleic acid or protein. For example, the presence of a polynucleotide sequence encoding EDG6 can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding EDG6. Nucleic acid amplification-based assays involve the use of

oligonucleotides selected from sequences encoding EDG6 to detect transformants which contain a EDG6 polynucleotide.

5 A variety of protocols for detecting and measuring the expression of EDG6, using either polyclonal or monoclonal antibodies specific for the polypeptide, are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radio-immunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay using monoclonal antibodies reactive to two non-interfering epitopes on EDG6 can be used, or a competitive binding assay can be  
10 employed.

A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to  
15 polynucleotides encoding EDG6 include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, sequences encoding EDG6 can be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and can be used to synthesize RNA probes *in vitro* by addition of labeled nucleotides and an appropriate  
20 RNA polymerase such as T7, T3, or SP6. These procedures can be conducted using a variety of commercially available kits (Amersham Pharmacia Biotech, Promega, and US Biochemical). Suitable reporter molecules or labels which can be used for ease of detection include radionuclides, enzymes, and fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles,  
25 and the like.

#### *Expression and Purification of Polypeptides*

30 Host cells transformed with EDG6 polynucleotides can be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The polypeptide produced by a transformed cell can be secreted or contained

intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing EDG6 polynucleotides can be designed to contain signal sequences which direct secretion of soluble EDG6 through a prokaryotic or eukaryotic cell membrane or which direct the membrane insertion of membrane-bound EDG6.

As discussed above, other constructions can be used to join a sequence encoding EDG6 to a nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Wash.). Inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and EDG6 also can be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing EDG6 and 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification by IMAC (immobilized metal ion affinity chromatography) Maddox, (1983)], while the enterokinase cleavage site provides a means for purifying EDG6 from the fusion protein [Porath, (1992)].

#### *Chemical Synthesis*

Sequences encoding EDG6 can be synthesized, in whole or in part, using chemical methods well known in the art. Alternatively, EDG6 itself can be produced using chemical methods to synthesize its amino acid sequence, such as by direct peptide synthesis using solid-phase techniques. Protein synthesis can either be performed using manual techniques or by automation. Automated synthesis can be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer).



Optionally, fragments of EDG6 can be separately synthesized and combined using chemical methods to produce a full-length molecule.

5 The newly synthesized peptide can be substantially purified by preparative high performance liquid chromatography. The composition of a synthetic EDG6 can be confirmed by amino acid analysis or sequencing. Additionally, any portion of the amino acid sequence of EDG6 can be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins to produce a variant polypeptide or a fusion protein.

#### 10 *Production of Altered Polypeptides*

As will be understood by those of skill in the art, it may be advantageous to produce EDG6 polynucleotides possessing non-naturally occurring codons. For example, 15 codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

20 The nucleotide sequences referred to herein can be engineered using methods generally known in the art to alter EDG6 polynucleotides for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the polypeptide or mRNA product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides 25 can be used to engineer the nucleotide sequences. For example, site-directed mutagenesis can be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations, and so forth.

*Antibodies*

Any type of antibody known in the art can be generated to bind specifically to an epitope of EDG6.

5 "Antibody" as used herein includes intact immunoglobulin molecules, as well as fragments thereof, such as Fab, F(ab')<sub>2</sub>, and Fv, which are capable of binding an epitope of EDG6. Typically, at least 6, 8, 10, or 12 contiguous amino acids are required to form an epitope. However, epitopes which involve non-contiguous  
10 amino acids may require more, *e.g.*, at least 15, 25, or 50 amino acid. An antibody which specifically binds to an epitope of EDG6 can be used therapeutically, as well as in immunochemical assays, such as Western blots, ELISAs, radioimmunoassays, immunohistochemical assays, immunoprecipitations, or other immunochemical assays known in the art. Various immunoassays can be used to identify antibodies  
15 having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays are well known in the art. Such immunoassays typically involve the measurement of complex formation between an immunogen and an antibody which specifically binds to the EDG6 immunogen.

20 Typically, an antibody which specifically binds to EDG6 provides a detection signal at least 5-, 10-, or 20-fold higher than a detection signal provided with other proteins when used in an immunochemical assay. Preferably, antibodies which specifically bind to EDG6 do not detect other proteins in immunochemical assays and can immunoprecipitate EDG6 from solution.

25 EDG6 can be used to immunize a mammal, such as a mouse, rat, rabbit, guinea pig, monkey, or human, to produce polyclonal antibodies. If desired, EDG6 can be conjugated to a carrier protein, such as bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin. Depending on the host species, various adjuvants can  
30 be used to increase the immunological response. Such adjuvants include, but are not limited to, Freund's adjuvant, mineral gels (*e.g.*, aluminum hydroxide), and surface

active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol). Among adjuvants used in humans, BCG (*bacilli Calmette-Guerin*) and *Corynebacterium parvum* are especially useful.

5

Monoclonal antibodies which specifically bind to EDG6 can be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These techniques include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique [Roberge, (1995)].

10

In addition, techniques developed for the production of "chimeric antibodies", the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. Monoclonal and other antibodies also can be "humanized" to prevent a patient from mounting an immune response against the antibody when it is used therapeutically. Such antibodies may be sufficiently similar in sequence to human antibodies to be used directly in therapy or may require alteration of a few key residues. Sequence differences between rodent antibodies and human sequences can be minimized by replacing residues which differ from those in the human sequences by site directed mutagenesis of individual residues or by grating of entire complementarity determining regions. Antibodies which specifically bind to EDG6 can contain antigen binding sites which are either partially or fully humanized, as disclosed in U.S. 5,565,332.

15

20

25

Alternatively, techniques described for the production of single chain antibodies can be adapted using methods known in the art to produce single chain antibodies which specifically bind to EDG6. Antibodies with related specificity, but of distinct idiotypic composition, can be generated by chain shuffling from random combinatorial immunoglobulin libraries. Single-chain antibodies also can be constructed using a DNA amplification method, such as PCR, using hybridoma cDNA as a

30

template. Single-chain antibodies can be mono- or bispecific, and can be bivalent or tetravalent. Construction of tetravalent, bispecific single-chain antibodies is taught. A nucleotide sequence encoding a single-chain antibody can be constructed using manual or automated nucleotide synthesis, cloned into an expression construct using standard recombinant DNA methods, and introduced into a cell to express the coding sequence, as described below. Alternatively, single-chain antibodies can be produced directly using, for example, filamentous phage technology.

Antibodies which specifically bind to EDG6 also can be produced by inducing *in vivo* production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents. Other types of antibodies can be constructed and used therapeutically in methods of the invention. For example, chimeric antibodies can be constructed as disclosed in WO 93/03151. Binding proteins which are derived from immunoglobulins and which are multivalent and multispecific, such as the "diabodies" described in WO 94/13804, also can be prepared.

Antibodies according to the invention can be purified by methods well known in the art. For example, antibodies can be affinity purified by passage over a column to which EDG6 is bound. The bound antibodies can then be eluted from the column using a buffer with a high salt concentration.

#### *Antisense Oligonucleotides*

Antisense oligonucleotides are nucleotide sequences which are complementary to a specific DNA or RNA sequence. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form complexes and block either transcription or translation. Preferably, an antisense oligonucleotide is at least 11 nucleotides in length, but can be at least 12, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides long. Longer sequences also can be used. Antisense

oligonucleotide molecules can be provided in a DNA construct and introduced into a cell as described above to decrease the level of EDG6 gene products in the cell.

Antisense oligonucleotides can be deoxyribonucleotides, ribonucleotides, or a combination of both. Oligonucleotides can be synthesized manually or by an automated synthesizer, by covalently linking the 5' end of one nucleotide with the 3' end of another nucleotide with non-phosphodiester internucleotide linkages such as alkylphosphonates, phosphorothioates, phosphorodithioates, alkylphosphonothioates, alkylphosphonates, phosphoramidates, phosphate esters, carbamates, acetamidate, carboxymethyl esters, carbonates, and phosphate triesters.

Modifications of EDG6 gene expression can be obtained by designing antisense oligonucleotides which will form duplexes to the control, 5', or regulatory regions of the EDG6 gene. Oligonucleotides derived from the transcription initiation site, *e.g.*, between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or chaperons. Therapeutic advances using triplex DNA have been described in the literature [Nicholls, (1993)]. An antisense oligonucleotide also can be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Precise complementarity is not required for successful complex formation between an antisense oligonucleotide and the complementary sequence of a EDG6 polynucleotide. Antisense oligonucleotides which comprise, for example, 2, 3, 4, or 5 or more stretches of contiguous nucleotides which are precisely complementary to a EDG6 polynucleotide, each separated by a stretch of contiguous nucleotides which are not complementary to adjacent EDG6 nucleotides, can provide sufficient targeting specificity for EDG6 mRNA. Preferably, each stretch of complementary contiguous nucleotides is at least 4, 5, 6, 7, or 8 or more nucleotides in length. Non-complementary intervening sequences are preferably 1, 2, 3, or 4 nucleotides in

length. One skilled in the art can easily use the calculated melting point of an antisense-sense pair to determine the degree of mismatching which will be tolerated between a particular antisense oligonucleotide and a particular EDG6 polynucleotide sequence. Antisense oligonucleotides can be modified without affecting their ability to hybridize to a EDG6 polynucleotide. These modifications can be internal or at one or both ends of the antisense molecule. For example, internucleoside phosphate linkages can be modified by adding cholesteryl or diamine moieties with varying numbers of carbon residues between the amino groups and terminal ribose. Modified bases and/or sugars, such as arabinose instead of ribose, or a 3', 5'-substituted oligonucleotide in which the 3' hydroxyl group or the 5' phosphate group are substituted, also can be employed in a modified antisense oligonucleotide. These modified oligonucleotides can be prepared by methods well known in the art.

### *Ribozymes*

Ribozymes are RNA molecules with catalytic activity [Uhlmann, (1987)]. Ribozymes can be used to inhibit gene function by cleaving an RNA sequence, as is known in the art. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of specific nucleotide sequences. The coding sequence of a EDG6 polynucleotide can be used to generate ribozymes which will specifically bind to mRNA transcribed from a EDG6 polynucleotide. Methods of designing and constructing ribozymes which can cleave other RNA molecules in trans in a highly sequence specific manner have been developed and described in the art. For example, the cleavage activity of ribozymes can be targeted to specific RNAs by engineering a discrete "hybridization" region into the ribozyme. The hybridization region contains a sequence complementary to the target RNA and thus specifically hybridizes with the target RNA.

Specific ribozyme cleavage sites within a EDG6 RNA target can be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target RNA containing the cleavage site can be evaluated for secondary structural features which may render the target inoperable. Suitability of candidate EDG6 RNA targets also can be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays. The nucleotide sequences shown in SEQ ID NO: 1 and its complement provide sources of suitable hybridization region sequences. Longer complementary sequences can be used to increase the affinity of the hybridization sequence for the target. The hybridizing and cleavage regions of the ribozyme can be integrally related such that upon hybridizing to the target RNA through the complementary regions, the catalytic region of the ribozyme can cleave the target.

Ribozymes can be introduced into cells as part of a DNA construct. Mechanical methods, such as microinjection, liposome-mediated transfection, electroporation, or calcium phosphate precipitation, can be used to introduce a ribozyme-containing DNA construct into cells in which it is desired to decrease EDG6 expression. Alternatively, if it is desired that the cells stably retain the DNA construct, the construct can be supplied on a plasmid and maintained as a separate element or integrated into the genome of the cells, as is known in the art. A ribozyme-encoding DNA construct can include transcriptional regulatory elements, such as a promoter element, an enhancer or UAS element, and a transcriptional terminator signal, for controlling transcription of ribozymes in the cells (U.S. 5,641,673). Ribozymes also can be engineered to provide an additional level of regulation, so that destruction of mRNA occurs only when both a ribozyme and a target gene are induced in the cells.

## Screening / Screening Assays

### *Regulators*

5 Regulators as used herein, refer to compounds that affect the activity of a EDG6 in vivo and/or in vivo. Regulators can be agonists and antagonists of a EDG6 polypeptide and can be compounds that exert their effect on the EDG6 activity via the expression, via post-translational modifications or by other means. Agonists of EDG6 are molecules which, when bound to EDG6, increase or prolong the activity of  
10 EDG6. Agonists of EDG6 include proteins, nucleic acids, carbohydrates, small molecules, or any other molecule which activate EDG6. Antagonists of EDG6 are molecules which, when bound to EDG6, decrease the amount or the duration of the activity of EDG6. Antagonists include proteins, nucleic acids, carbohydrates, antibodies, small molecules, or any other molecule which decrease the activity of  
15 EDG6.

The term "modulate", as it appears herein, refers to a change in the activity of EDG6 polypeptide. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immuno-  
20 logical properties of EDG6.

As used herein, the terms "specific binding" or "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, or an antagonist. The interaction is dependent upon the presence of a particular structure of the protein recognized by the binding molecule (i.e., the antigenic determinant or epitope). For  
25 example, if an antibody is specific for epitope "A" the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.



The invention provides methods (also referred to herein as "screening assays") for identifying compounds which can be used for the treatment of hematological and cardiovascular diseases, disorders of the peripheral and central nervous system, COPD, asthma, genito-urological disorders and inflammation diseases. The methods entail the identification of candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other molecules) which bind to EDG6 and/or have a stimulatory or inhibitory effect on the biological activity of EDG6 or its expression and then determining which of these compounds have an effect on symptoms or diseases regarding the hematological and cardiovascular diseases, disorders of the peripheral and central nervous system, COPD, asthma, genito-urological disorders and inflammation diseases in an *in vivo* assay.

Candidate or test compounds or agents which bind to EDG6 and/or have a stimulatory or inhibitory effect on the activity or the expression of EDG6 are identified either in assays that employ cells which express EDG6 on the cell surface (cell-based assays) or in assays with isolated EDG6 (cell-free assays). The various assays can employ a variety of variants of EDG6 (e.g., full-length EDG6, a biologically active fragment of EDG6, or a fusion protein which includes all or a portion of EDG6). Moreover, EDG6 can be derived from any suitable mammalian species (e.g., human EDG6, rat EDG6 or murine EDG6). The assay can be a binding assay entailing direct or indirect measurement of the binding of a test compound or a known EDG6 ligand to EDG6. The assay can also be an activity assay entailing direct or indirect measurement of the activity of EDG6. The assay can also be an expression assay entailing direct or indirect measurement of the expression of EDG6 mRNA or EDG6 protein. The various screening assays are combined with an *in vivo* assay entailing measuring the effect of the test compound on the symptoms of hematological and cardiovascular diseases, disorders of the peripheral and central nervous system, COPD, asthma, genito-urological disorders and inflammation diseases.

In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of a membrane-bound (cell surface expressed) form of EDG6. Such assays can employ full-length EDG6, a biologically active fragment of EDG6, or a fusion protein which includes all or a portion of EDG6. As described in greater detail below, the test compound can be obtained by any suitable means, e.g., from conventional compound libraries. Determining the ability of the test compound to bind to a membrane-bound form of EDG6 can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the EDG6 - expressing cell can be measured by detecting the labeled compound in a complex. For example, the test compound can be labelled with  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^3\text{H}$ , either directly or indirectly, and the radioisotope detected by direct counting of radio-emission or by scintillation counting. Alternatively, the test compound can be enzymatically labelled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.

In a competitive binding format, the assay comprises contacting EDG6 expressing cell with a known compound which binds to EDG6 to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the EDG6 expressing cell, wherein determining the ability of the test compound to interact with the EDG6 expressing cell comprises determining the ability of the test compound to preferentially bind the EDG6 expressing cell as compared to the known compound.

In another embodiment, the assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of EDG6 (e.g., full-length EDG6, a biologically active fragment of EDG6, or a fusion protein which includes all or a portion of EDG6) expressed on the cell surface with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the membrane-bound form of EDG6. Determining the ability of the test compound to

modulate the activity of the membrane-bound form of EDG6 can be accomplished by any method suitable for measuring the activity of EDG6, e.g., any method suitable for measuring the activity of a G-protein coupled receptor or other seven-transmembrane receptor (described in greater detail below). The activity of a seven-transmembrane receptor can be measured in a number of ways, not all of which are suitable for any given receptor. Among the measures of activity are: alteration in intracellular  $\text{Ca}^{2+}$  concentration, activation of phospholipase C, alteration in intracellular inositol triphosphate ( $\text{IP}_3$ ) concentration, alteration in intracellular diacylglycerol (DAG) concentration, and alteration in intracellular adenosine cyclic 3', 5'-monophosphate (cAMP) concentration.

Determining the ability of the test compound to modulate the activity of EDG6 can be accomplished, for example, by determining the ability of EDG6 to bind to or interact with a target molecule. The target molecule can be a molecule with which EDG6 binds or interacts with in nature, for example, a molecule on the surface of a cell which expresses EDG6, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. The target molecule can be a component of a signal transduction pathway which facilitates transduction of an extracellular signal (e.g., a signal generated by binding of a EDG6 ligand, through the cell membrane and into the cell. The target EDG6 molecule can be, for example, a second intracellular protein which has catalytic activity or a protein which facilitates the association of downstream signaling molecules with EDG6.

Determining the ability of EDG6 to bind to or interact with a target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of a polypeptide of the invention to bind to or interact with a target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (e.g., intracellular  $\text{Ca}^{2+}$ , diacylglycerol,  $\text{IP}_3$ , etc.), detecting catalytic/enzymatic activity of

the target on an appropriate substrate, detecting the induction of a reporter gene (e.g., a regulatory element that is responsive to a polypeptide of the invention operably linked to a nucleic acid encoding a detectable marker, e.g., luciferase), or detecting a cellular response.

5 The present invention also includes cell-free assays. Such assays involve contacting a form of EDG6 (e.g., full-length EDG6, a biologically active fragment of EDG6, or a fusion protein comprising all or a portion of EDG6) with a test compound and determining the ability of the test compound to bind to EDG6. Binding of the test  
10 compound to EDG6 can be determined either directly or indirectly as described above. In one embodiment, the assay includes contacting EDG6 with a known compound which binds EDG6 to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with EDG6, wherein determining the ability of the test compound to interact with  
15 EDG6 comprises determining the ability of the test compound to preferentially bind to EDG6 as compared to the known compound.

The cell-free assays of the present invention are amenable to use of either a  
20 membrane-bound form of EDG6 or a soluble fragment thereof. In the case of cell-free assays comprising the membrane-bound form of the polypeptide, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of the polypeptide is maintained in solution. Examples of such solubilizing agents include but are not limited to non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton X-100, Triton X-114, Thesit, Isotridecypoly(ethylene glycol  
25 ether)<sub>n</sub>, 3-[(3-cholamidopropyl)dimethylamminio]-1-propane sulfonate (CHAPS), 3-[(3-cholamidopropyl)dimethylamminio]-2-hydroxy-1-propane sulfonate (CHAPSO), or N-dodecyl=N,N-dimethyl-3-ammonio-1-propane sulfonate.

30 In various embodiments of the above assay methods of the present invention, it may be desirable to immobilize EDG6 (or a EDG6 target molecule) to facilitate separation

of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to EDG6, or interaction of EDG6 with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase (GST) fusion proteins or glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical; St. Louis, Mo.) or glutathione derivatized microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or EDG6, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtitre plate wells are washed to remove any unbound components and complex formation is measured either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of binding or activity of EDG6 can be determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either EDG6 or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated polypeptide of the invention or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals; Rockford, Ill.), and immobilized in the wells of streptavidin-coated plates (Pierce Chemical). Alternatively, antibodies reactive with EDG6 or target molecules but which do not interfere with binding of the polypeptide of the invention to its target molecule can be derivatized to the wells of the plate, and unbound target or polypeptide of the invention trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes

using antibodies reactive with EDG6 or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with EDG6 or target molecule.

5 The screening assay can also involve monitoring the expression of EDG6. For example, regulators of expression of EDG6 can be identified in a method in which a cell is contacted with a candidate compound and the expression of EDG6 protein or mRNA in the cell is determined. The level of expression of EDG6 protein or mRNA  
10 the presence of the candidate compound is compared to the level of expression of EDG6 protein or mRNA in the absence of the candidate compound. The candidate compound can then be identified as a regulator of expression of EDG6 based on this comparison. For example, when expression of EDG6 protein or mRNA protein is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of EDG6  
15 protein or mRNA expression. Alternatively, when expression of EDG6 protein or mRNA is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of EDG6 protein or mRNA expression. The level of EDG6 protein or mRNA expression in the cells can be determined by methods described below.

#### 20 *Binding Assays*

For binding assays, the test compound is preferably a small molecule which binds to and occupies the active site of EDG6 polypeptide, thereby making the ligand binding  
25 site inaccessible to substrate such that normal biological activity is prevented. Examples of such small molecules include, but are not limited to, small peptides or peptide-like molecules. Potential ligands which bind to a polypeptide of the invention include, but are not limited to, the natural ligands of known EDG6 GPCRs and analogues or derivatives thereof.

In binding assays, either the test compound or the EDG6 polypeptide can comprise a detectable label, such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horseradish peroxidase, alkaline phosphatase, or luciferase. Detection of a test compound which is bound to EDG6 polypeptide can then be accomplished, for example, by direct counting of radioemmission, by scintillation counting, or by determining conversion of an appropriate substrate to a detectable product. Alternatively, binding of a test compound to a EDG6 polypeptide can be determined without labeling either of the interactants. For example, a microphysiometer can be used to detect binding of a test compound with a EDG6 polypeptide. A microphysiometer (e.g., Cytosensor™) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between a test compound and EDG6 [Haseloff, (1988)].

Determining the ability of a test compound to bind to EDG6 also can be accomplished using a technology such as real-time Bimolecular Interaction Analysis (BIA) [McConnell, (1992); Sjolander, (1991)]. BIA is a technology for studying bio-specific interactions in real time, without labeling any of the interactants (e.g., BIAcore™). Changes in the optical phenomenon surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.

In yet another aspect of the invention, a EDG6-like polypeptide can be used as a "bait protein" in a two-hybrid assay or three-hybrid assay [Szabo, (1995); U.S. 5,283,317], to identify other proteins which bind to or interact with EDG6 and modulate its activity.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. For example, in one construct, polynucleotide encoding EDG6 can be fused to a polynucleotide encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct a DNA

sequence that encodes an unidentified protein ("prey" or "sample") can be fused to a polynucleotide that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact *in vivo* to form a protein-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ), which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected, and cell colonies containing the functional transcription factor can be isolated and used to obtain the DNA sequence encoding the protein which interacts with EDG6.

It may be desirable to immobilize either the EDG6 (or polynucleotide) or the test compound to facilitate separation of the bound form from unbound forms of one or both of the interactants, as well as to accommodate automation of the assay. Thus, either the EDG6-like polypeptide (or polynucleotide) or the test compound can be bound to a solid support. Suitable solid supports include, but are not limited to, glass or plastic slides, tissue culture plates, microtiter wells, tubes, silicon chips, or particles such as beads (including, but not limited to, latex, polystyrene, or glass beads). Any method known in the art can be used to attach EDG6-like polypeptide (or polynucleotide) or test compound to a solid support, including use of covalent and non-covalent linkages, passive absorption, or pairs of binding moieties attached respectively to the polypeptide (or polynucleotide) or test compound and the solid support. Test compounds are preferably bound to the solid support in an array, so that the location of individual test compounds can be tracked. Binding of a test compound to EDG6 (or a polynucleotide encoding for EDG6) can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and microcentrifuge tubes.

In one embodiment, EDG6 is a fusion protein comprising a domain that allows binding of EDG6 to a solid support. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St.



Louis, Mo.) or glutathione derivatized microtiter plates, which are then combined with the test compound or the test compound and the non-adsorbed EDG6; the mixture is then incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components. Binding of the interactants can be determined either directly or indirectly, as described above. Alternatively, the complexes can be dissociated from the solid support before binding is determined.

Other techniques for immobilizing proteins or polynucleotides on a solid support also can be used in the screening assays of the invention. For example, either EDG6 (or a polynucleotide encoding EDG6) or a test compound can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated EDG6 (or a polynucleotide encoding biotinylated EDG6) or test compounds can be prepared from biotin-NHS (N-hydroxysuccinimide) using techniques well known in the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, Ill.) and immobilized in the wells of streptavidin-coated plates (Pierce Chemical). Alternatively, antibodies which specifically bind to EDG6, polynucleotide, or a test compound, but which do not interfere with a desired binding site, such as the active site of EDG6, can be derivatized to the wells of the plate. Unbound target or protein can be trapped in the wells by antibody conjugation.

Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies which specifically bind to EDG6 polypeptide or test compound, enzyme-linked assays which rely on detecting an activity of EDG6 polypeptide, and SDS gel electrophoresis under non-reducing conditions.

Screening for test compounds which bind to a EDG6 polypeptide or polynucleotide also can be carried out in an intact cell. Any cell which comprises a EDG6 polypeptide or polynucleotide can be used in a cell-based assay system. A EDG6 polynucleotide can be naturally occurring in the cell or can be introduced using

techniques such as those described above. Binding of the test compound to EDG6 or a polynucleotide encoding EDG6 is determined as described above.

### *Functional Assays*

5

10

Test compounds can be tested for the ability to increase or decrease EDG6 activity of a EDG6 polypeptide. The EDG6 activity can be measured, for example, using methods described in the specific examples, below. EDG6 activity can be measured after contacting either a purified EDG6, a cell membrane preparation, or an intact cell with a test compound. A test compound which decreases EDG6 activity by at least about 10, preferably about 50, more preferably about 75, 90, or 100% is identified as a potential agent for decreasing EDG6 activity. A test compound which increases EDG6 activity by at least about 10, preferably about 50, more preferably about 75, 90, or 100% is identified as a potential agent for increasing EDG6 activity.

15

20

25

One such screening procedure involves the use of melanophores which are transfected to express EDG6. Such a screening technique is described in PCT WO 92/01810 published Feb. 6, 1992. Thus, for example, such an assay may be employed for screening for a compound which inhibits activation of the receptor polypeptide of the present invention by contacting the melanophore cells which encode the receptor with both the receptor ligand and a compound to be screened. Inhibition of the signal generated by the ligand indicates that a compound is a potential antagonist for the receptor, *i.e.*, inhibits activation of the receptor. The screen may be employed for identifying a compound which activates the receptor by contacting such cells with compounds to be screened and determining whether each compound generates a signal, *i.e.*, activates the receptor.

30

Other screening techniques include the use of cells which express EDG6 (for example, transfected CHO cells) in a system which measures extracellular pH changes caused by receptor activation [Iwabuchi, (1993)]. For example, compounds may be contacted with a cell which expresses the receptor polypeptide of the present

invention and a second messenger response, e.g., signal transduction or pH changes, can be measured to determine whether the potential compound activates or inhibits the receptor. Another such screening technique involves introducing RNA encoding EDG6 into *Xenopus* oocytes to transiently express the receptor. The receptor oocytes can then be contacted with the receptor ligand and a compound to be screened, followed by detection of inhibition or activation of a calcium signal in the case of screening for compounds which are thought to inhibit activation of the receptor.

Another screening technique involves expressing EDG6 in cells in which the receptor is linked to a phospholipase C or D. Such cells include endothelial cells, smooth muscle cells, embryonic kidney cells, etc. The screening may be accomplished as described above by quantifying the degree of activation of the receptor from changes in the phospholipase activity.

#### *Gene Expression*

In another embodiment, test compounds which increase or decrease EDG6 gene expression are identified. As used herein, the term "correlates with expression of a polynucleotide" indicates that the detection of the presence of nucleic acids, the same or related to a nucleic acid sequence encoding EDG6, by northern analysis or real-time PCR is indicative of the presence of nucleic acids encoding EDG6 in a sample, and thereby correlates with expression of the transcript from the polynucleotide encoding EDG6. The term "microarray", as used herein, refers to an array of distinct polynucleotides or oligonucleotides arrayed on a substrate, such as paper, nylon or any other type of membrane, filter, chip, glass slide, or any other suitable solid support. A EDG6 polynucleotide is contacted with a test compound, and the expression of an RNA or polypeptide product of EDG6 polynucleotide is determined. The level of expression of appropriate mRNA or polypeptide in the presence of the test compound is compared to the level of expression of mRNA or polypeptide in the absence of the test compound. The test compound can then be identified as a regulator of expression based on this comparison. For example, when

expression of mRNA or polypeptide is greater in the presence of the test compound than in its absence, the test compound is identified as a stimulator or enhancer of the mRNA or polypeptide expression. Alternatively, when expression of the mRNA or polypeptide is less in the presence of the test compound than in its absence, the test compound is identified as an inhibitor of the mRNA or polypeptide expression.

The level of EDG6 mRNA or polypeptide expression in the cells can be determined by methods well known in the art for detecting mRNA or polypeptide. Either qualitative or quantitative methods can be used. The presence of polypeptide products of EDG6 polynucleotide can be determined, for example, using a variety of techniques known in the art, including immunochemical methods such as radio-immunoassay, Western blotting, and immunohistochemistry. Alternatively, polypeptide synthesis can be determined *in vivo*, in a cell culture, or in an *in vitro* translation system by detecting incorporation of labelled amino acids into EDG6.

Such screening can be carried out either in a cell-free assay system or in an intact cell. Any cell which expresses EDG6 polynucleotide can be used in a cell-based assay system. The EDG6 polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those described above. Either a primary culture or an established cell line can be used.

#### *Test Compounds*

Suitable test compounds for use in the screening assays of the invention can be obtained from any suitable source, e.g., conventional compound libraries. The test compounds can also be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are

applicable to peptide, non-peptide oligomer or small molecule libraries of compounds [Lam, (1997)]. Examples of methods for the synthesis of molecular libraries can be found in the art. Libraries of compounds may be presented in solution or on beads, bacteria, spores, plasmids or phage.

5

### *Modeling of Regulators*

Computer modeling and searching technologies permit identification of compounds, or the improvement of already identified compounds, that can modulate EDG6  
10 expression or activity. Having identified such a compound or composition, the active sites or regions are identified. Such active sites might typically be ligand binding sites, such as the interaction domain of the ligand with EDG6. The active site can be identified using methods known in the art including, for example, from the amino acid sequences of peptides, from the nucleotide sequences of nucleic acids, or from  
15 study of complexes of the relevant compound or composition with its natural ligand. In the latter case, chemical or X-ray crystallographic methods can be used to find the active site by finding where on the factor the complexed ligand is found.

Next, the three dimensional geometric structure of the active site is determined. This  
20 can be done by known methods, including X-ray crystallography, which can determine a complete molecular structure. On the other hand, solid or liquid phase NMR can be used to determine certain intramolecular distances. Any other experimental method of structure determination can be used to obtain partial or complete geometric structures. The geometric structures may be measured with a  
25 complexed ligand, natural or artificial, which may increase the accuracy of the active site structure determined.

If an incomplete or insufficiently accurate structure is determined, the methods of computer based numerical modeling can be used to complete the structure or  
30 improve its accuracy. Any recognized modeling method may be used, including parameterized models specific to particular biopolymers such as proteins or nucleic

acids, molecular dynamics models based on computing molecular motions, statistical mechanics models based on thermal ensembles, or combined models. For most types of models, standard molecular force fields, representing the forces between constituent atoms and groups, are necessary, and can be selected from force fields known in physical chemistry. The incomplete or less accurate experimental structures can serve as constraints on the complete and more accurate structures computed by these modeling methods.

Finally, having determined the structure of the active site, either experimentally, by modeling, or by a combination, candidate modulating compounds can be identified by searching databases containing compounds along with information on their molecular structure. Such a search seeks compounds having structures that match the determined active site structure and that interact with the groups defining the active site. Such a search can be manual, but is preferably computer assisted. These compounds found from this search are potential EDG6 modulating compounds.

Alternatively, these methods can be used to identify improved modulating compounds from an already known modulating compound or ligand. The composition of the known compound can be modified and the structural effects of modification can be determined using the experimental and computer modeling methods described above applied to the new composition. The altered structure is then compared to the active site structure of the compound to determine if an improved fit or interaction results. In this manner systematic variations in composition, such as by varying side groups, can be quickly evaluated to obtain modified modulating compounds or ligands of improved specificity or activity.

#### **Therapeutic Indications and Methods**

It was found by the present applicant that EDG6 is expressed in various human tissues.

*Neurology*

CNS disorders include disorders of the central nervous system as well as disorders of the peripheral nervous system.

5

CNS disorders include, but are not limited to brain injuries, cerebrovascular diseases and their consequences, Parkinson's disease, corticobasal degeneration, motor neuron disease, dementia, including ALS, multiple sclerosis, traumatic brain injury, stroke, post-stroke, post-traumatic brain injury, and small-vessel cerebrovascular disease.

10

Dementias, such as Alzheimer's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia and Parkinsonism linked to chromosome 17, frontotemporal dementias, including Pick's disease, progressive nuclear palsy, corticobasal degeneration, Huntington's disease, thalamic degeneration, Creutzfeld-Jakob dementia, HIV dementia, schizophrenia with dementia, and Korsakoff's psychosis, within the meaning of the definition are also considered to be CNS disorders.

15

Similarly, cognitive-related disorders, such as mild cognitive impairment, age-associated memory impairment, age-related cognitive decline, vascular cognitive impairment, attention deficit disorders, attention deficit hyperactivity disorders, and memory disturbances in children with learning disabilities are also considered to be CNS disorders.

20

Pain, within the meaning of this definition, is also considered to be a CNS disorder.

25

Pain can be associated with CNS disorders, such as multiple sclerosis, spinal cord injury, sciatica, failed back surgery syndrome, traumatic brain injury, epilepsy, Parkinson's disease, post-stroke, and vascular lesions in the brain and spinal cord (e.g., infarct, hemorrhage, vascular malformation). Non-central neuropathic pain includes that associated with post mastectomy pain, phantom feeling, reflex sympathetic dystrophy (RSD), trigeminal neuralgia, radioculopathy, post-surgical pain, HIV/AIDS related pain, cancer pain, metabolic neuropathies (e.g., diabetic

30

neuropathy, vasculitic neuropathy secondary to connective tissue disease), paraneoplastic polyneuropathy associated, for example, with carcinoma of lung, or leukemia, or lymphoma, or carcinoma of prostate, colon or stomach, trigeminal neuralgia, cranial neuralgias, and post-herpetic neuralgia. Pain associated with peripheral nerve damage, central pain (i.e. due to cerebral ischemia) and various chronic pain i.e., lumbago, back pain (low back pain), inflammatory and/or rheumatic pain. Headache pain (for example, migraine with aura, migraine without aura, and other migraine disorders), episodic and chronic tension-type headache, tension-type like headache, cluster headache, and chronic paroxysmal hemicrania are also CNS disorders.

Visceral pain such as pancreatitis, intestinal cystitis, dysmenorrhea, irritable Bowel syndrome, Crohn's disease, biliary colic, ureteral colic, myocardial infarction and pain syndromes of the pelvic cavity, e.g., vulvodynia, orchialgia, urethral syndrome and protatodynia are also CNS disorders.

Also considered to be a disorder of the nervous system are acute pain, for example postoperative pain, and pain after trauma.

The human EDG6 is highly expressed in the following brain tissues: Alzheimer brain, Alzheimer brain cerebellum, Alzheimer cerebral cortex, posteroventral thalamus, dorsomedial thalamus, spinal cord (ventral horn), spinal cord (dorsal horn), neuroblastoma IMR32 cells, astrocytes. The expression in brain tissues and in particular the differential expression between diseased tissue Alzheimer brain and healthy tissue brain, between diseased tissue Alzheimer brain cerebellum and healthy tissue, between diseased tissue Alzheimer cerebral cortex and healthy tissue cerebral cortex demonstrates that the human EDG6 or mRNA can be utilized to diagnose nervous system diseases. Additionally the activity of the human EDG6 can be modulated to treat nervous system diseases.



### *Cardiovascular Disorders*

Heart failure is defined as a pathophysiological state in which an abnormality of cardiac function is responsible for the failure of the heart to pump blood at a rate commensurate with the requirement of the metabolizing tissue. It includes all forms of pumping failures such as high-output and low-output, acute and chronic, right-sided or left-sided, systolic or diastolic, independent of the underlying cause.

Myocardial infarction (MI) is generally caused by an abrupt decrease in coronary blood flow that follows a thrombotic occlusion of a coronary artery previously narrowed by arteriosclerosis. MI prophylaxis (primary and secondary prevention) is included as well as the acute treatment of MI and the prevention of complications.

Ischemic diseases are conditions in which the coronary flow is restricted resulting in a perfusion which is inadequate to meet the myocardial requirement for oxygen. This group of diseases includes stable angina, unstable angina and asymptomatic ischemia.

Arrhythmias include all forms of atrial and ventricular tachyarrhythmias, atrial tachycardia, atrial flutter, atrial fibrillation, atrio-ventricular reentrant tachycardia, preexcitation syndrome, ventricular tachycardia, ventricular flutter, ventricular fibrillation, as well as bradycardic forms of arrhythmias.

Hypertensive vascular diseases include primary as well as all kinds of secondary arterial hypertension, renal, endocrine, neurogenic, others. The genes may be used as drug targets for the treatment of hypertension as well as for the prevention of all complications arising from cardiovascular diseases.

Peripheral vascular diseases are defined as vascular diseases in which arterial and/or venous flow is reduced resulting in an imbalance between blood supply and tissue oxygen demand. It includes chronic peripheral arterial occlusive disease (PAOD),

acute arterial thrombosis and embolism, inflammatory vascular disorders, Raynaud's phenomenon and venous disorders.

5 Atherosclerosis is a cardiovascular disease in which the vessel wall is remodeled, compromising the lumen of the vessel. The atherosclerotic remodeling process involves accumulation of cells, both smooth muscle cells and monocyte/macrophage inflammatory cells, in the intima of the vessel wall. These cells take up lipid, likely from the circulation, to form a mature atherosclerotic lesion. Although the formation of these lesions is a chronic process, occurring over decades of an adult human life,  
10 the majority of the morbidity associated with atherosclerosis occurs when a lesion ruptures, releasing thrombogenic debris that rapidly occludes the artery. When such an acute event occurs in the coronary artery, myocardial infarction can ensue, and in the worst case, can result in death.

15 The formation of the atherosclerotic lesion can be considered to occur in five overlapping stages such as migration, lipid accumulation, recruitment of inflammatory cells, proliferation of vascular smooth muscle cells, and extracellular matrix deposition. Each of these processes can be shown to occur in man and in animal models of atherosclerosis, but the relative contribution of each to the pathology and  
20 clinical significance of the lesion is unclear.

Thus, a need exists for therapeutic methods and agents to treat cardiovascular pathologies, such as atherosclerosis and other conditions related to coronary artery disease.

25 Cardiovascular diseases include but are not limited to disorders of the heart and the vascular system. like congestive heart failure, myocardial infarction, ischemic diseases of the heart, all kinds of atrial and ventricular arrhythmias, hypertensive vascular diseases, peripheral vascular diseases, and atherosclerosis.

Too high or too low levels of fats in the bloodstream, especially cholesterol, can cause long-term problems. The risk to develop atherosclerosis and coronary artery or carotid artery disease (and thus the risk of having a heart attack or stroke) increases with the total cholesterol level increasing. Nevertheless, extremely low cholesterol levels may not be healthy. Examples of disorders of lipid metabolism are hyperlipidemia (abnormally high levels of fats (cholesterol, triglycerides, or both) in the blood, may be caused by family history of hyperlipidemia), obesity, a high-fat diet, lack of exercise, moderate to high alcohol consumption, cigarette smoking, poorly controlled diabetes, and an underactive thyroid gland), hereditary hyperlipidemias (type I hyperlipoproteinemia (familial hyperchylomicronemia), type II hyperlipoproteinemia (familial hypercholesterolemia), type III hyperlipoproteinemia, type IV hyperlipoproteinemia, or type V hyperlipoproteinemia), hypolipoproteinemia, lipidoses (caused by abnormalities in the enzymes that metabolize fats), Gaucher's disease, Niemann-Pick disease, Fabry's disease, Wolman's disease, cerebrotendinous xanthomatosis, sitosterolemia, Refsum's disease, or Tay-Sachs disease.

Kidney disorders may lead to hypertension or hypotension. Examples for kidney problems possibly leading to hypertension are renal artery stenosis, pyelonephritis, glomerulonephritis, kidney tumors, polycystic kidney disease, injury to the kidney, or radiation therapy affecting the kidney. Excessive urination may lead to hypotension.

The human EDG6 is highly expressed in the following cardiovascular related tissues: heart atrium (left), pulmonic valve, coronary artery endothel cells. Expression in the above mentioned tissues demonstrates that the human EDG6 or mRNA can be utilized to diagnose of cardiovascular diseases. Additionally the activity of the human EDG6 can be modulated to treat cardiovascular diseases.

*Hematological Disorders*

Hematological disorders comprise diseases of the blood and all its constituents as well as diseases of organs and tissues involved in the generation or degradation of all the constituents of the blood. They include but are not limited to 1) Anemias, 2) Myeloproliferative Disorders, 3) Hemorrhagic Disorders, 4) Leukopenia, 5) Eosinophilic Disorders, 6) Leukemias, 7) Lymphomas, 8) Plasma Cell Dyscrasias, 9) Disorders of the Spleen in the course of hematological disorders. Disorders according to 1) include, but are not limited to anemias due to defective or deficient hem synthesis, deficient erythropoiesis. Disorders according to 2) include, but are not limited to polycythemia vera, tumor-associated erythrocytosis, myelofibrosis, thrombocythemia. Disorders according to 3) include, but are not limited to vasculitis, thrombocytopenia, heparin-induced thrombocytopenia, thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, hereditary and acquired disorders of platelet function, hereditary coagulation disorders. Disorders according to 4) include, but are not limited to neutropenia, lymphocytopenia. Disorders according to 5) include, but are not limited to hypereosinophilia, idiopathic hypereosinophilic syndrome. Disorders according to 6) include, but are not limited to acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia, myelodysplastic syndrome. Disorders according to 7) include, but are not limited to Hodgkin's disease, non-Hodgkin's lymphoma, Burkitt's lymphoma, mycosis fungoides cutaneous T-cell lymphoma. Disorders according to 8) include, but are not limited to multiple myeloma, macroglobulinemia, heavy chain diseases. In extension of the preceding idiopathic thrombocytopenic purpura, iron deficiency anemia, megaloblastic anemia (vitamin B12 deficiency), aplastic anemia, thalassemia, malignant lymphoma bone marrow invasion, malignant lymphoma skin invasion, hemolytic uremic syndrome, giant platelet disease are considered to be hematological diseases too.

Hematological disorders include conditions where platelet counts are low (thrombocytopenia) including but not limited to drug-induced thrombocytopenia (e.g. following

cancer chemotherapy), radio-therapy-induced thrombocytopenia, thrombocytopenia following bone marrow transplantation, immune thrombocytopenia (due to increased degradation of platelets) and congenital thrombocytopenia.

5 The human EDG6 is highly expressed in the following tissues of the hematological system: leukocytes (peripheral blood), bone marrow, erythrocytes, thymus, bone marrow CD71+ cells, bone marrow CD33+ cells, bone marrow CD34+ cells, bone marrow CD15+ cells, cord blood CD71+ cells, cord blood CD34+ cells, neutrophils  
10 cord blood, neutrophils peripheral blood, spleen liver cirrhosis. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue spleen liver cirrhosis and healthy tissue spleen demonstrates that the human EDG6 or mRNA can be utilized to diagnose of hematological diseases. Additionally the activity of the human EDG6 can be modulated to treat hematological disorders.

15

#### *Gastrointestinal and Liver Diseases*

Gastrointestinal diseases comprise primary or secondary, acute or chronic diseases of the organs of the gastrointestinal tract which may be acquired or inherited, benign or  
20 malignant or metaplastic, and which may affect the organs of the gastrointestinal tract or the body as a whole. They comprise but are not limited to 1) disorders of the esophagus like achalasia, vigorous achalasia, dysphagia, cricopharyngeal incoordination, pre-esophageal dysphagia, diffuse esophageal spasm, globus sensation, Barrett's metaplasia, gastroesophageal reflux, 2) disorders of the stomach and  
25 duodenum like functional dyspepsia, inflammation of the gastric mucosa, gastritis, stress gastritis, chronic erosive gastritis, atrophy of gastric glands, metaplasia of gastric tissues, gastric ulcers, duodenal ulcers, neoplasms of the stomach, 3) disorders of the pancreas like acute or chronic pancreatitis, insufficiency of the exocrine or endocrine tissues of the pancreas like steatorrhea, diabetes, neoplasms of the  
30 exocrine or endocrine pancreas like 3.1) multiple endocrine neoplasia syndrome, ductal adenocarcinoma, cystadenocarcinoma, islet cell tumors, insulinoma,

gastrinoma, carcinoid tumors, glucagonoma, Zollinger-Ellison syndrome, Vipoma syndrome, malabsorption syndrome, 4) disorders of the bowel like chronic inflammatory diseases of the bowel, Cröhn's disease, ileus, diarrhea and constipation, colonic inertia, megacolon, malabsorption syndrome, ulcerative colitis, 5 4.1) functional bowel disorders like irritable bowel syndrome, 4.2) neoplasms of the bowel like familial polyposis, adenocarcinoma, primary malignant lymphoma, carcinoid tumors, Kaposi's sarcoma, polyps, cancer of the colon and rectum.

10 Liver diseases comprise primary or secondary, acute or chronic diseases or injury of the liver which may be acquired or inherited, benign or malignant, and which may affect the liver or the body as a whole. They comprise but are not limited to disorders of the bilirubin metabolism, jaundice, syndroms of Gilbert's, Crigler-Najjar, Dubin-Johnson and Rotor; intrahepatic cholestasis, hepatomegaly, portal hypertension, ascites, Budd-Chiari syndrome, portal-systemic encephalopathy, fatty liver, steatosis, 15 Reye's syndrome, liver diseases due to alcohol, alcoholic hepatitis or cirrhosis, fibrosis and cirrhosis, fibrosis and cirrhosis of the liver due to inborn errors of metabolism or exogenous substances, storage diseases, syndromes of Gaucher's, Zellweger's, Wilson's - disease, acute or chronic hepatitis, viral hepatitis and its variants, inflammatory conditions of the liver due to viruses, bacteria, fungi, 20 protozoa, helminths; drug induced disorders of the liver, chronic liver diseases like primary sclerosing cholangitis, alpha<sub>1</sub>-antitrypsin-deficiency, primary biliary cirrhosis, postoperative liver disorders like postoperative intrahepatic cholestasis, hepatic granulomas, vascular liver disorders associated with systemic disease, benign or malignant neoplasms of the liver, disturbance of liver metabolism in the new-born or prematurely born. 25

The human EDG6 is highly expressed in the following tissues of the gastro-enterological system: esophagus, stomach, small intestine, ileum, ileum chronic inflammation, rectum, liver liver cirrhosis. The expression in the above mentioned 30 tissues and in particular the differential expression between diseased tissue ileum chronic inflammation and healthy tissue ileum, between diseased tissue liver

cirrhosis and healthy tissue liver demonstrates that the human EDG6 or mRNA can be utilized to diagnose of gastroenterological disorders. Additionally the activity of the human EDG6 can be modulated to treat gastroenterological disorders.

## 5 *Inflammatory Diseases*

Inflammatory diseases comprise diseases triggered by cellular or non-cellular mediators of the immune system or tissues causing the inflammation of body tissues and subsequently producing an acute or chronic inflammatory condition. Examples  
10 for such inflammatory diseases are hypersensitivity reactions of type I – IV, for example but not limited to hypersensitivity diseases of the lung including asthma, atopic diseases, allergic rhinitis or conjunctivitis, angioedema of the lids, hereditary angioedema, antireceptor hypersensitivity reactions and autoimmune diseases, Hashimoto's thyroiditis, systemic lupus erythematosus, Goodpasture's syndrome,  
15 pemphigus, myasthenia gravis, Grave's and Raynaud's disease, type B insulin-resistant diabetes, rheumatoid arthritis, psoriasis, Crohn's disease, scleroderma, mixed connective tissue disease, polymyositis, sarcoidosis, glomerulonephritis, acute or chronic host versus graft reactions.

20 The human EDG6 is highly expressed in the following tissues of the immune system and tissues responsive to components of the immune system as well as in the following tissues responsive to mediators of inflammation: ileum chronic inflammation, liver liver cirrhosis, leukocytes (peripheral blood), bone marrow, bone marrow CD15+ cells, spleen liver cirrhosis, lung COPD. The expression in the above  
25 mentioned tissues and in particular the differential expression between diseased tissue ileum chronic inflammation and healthy tissue ileum, between diseased tissue liver liver cirrhosis and healthy tissue liver, between diseased tissue spleen liver cirrhosis and healthy tissue spleen, between diseased tissue lung COPD and healthy tissue lung demonstrates that the human EDG6 or mRNA can be utilized to diagnose  
30 of inflammatory diseases. Additionally the activity of the human EDG6 can be modulated to treat inflammatory diseases.

*Disorders Related to Pulmology*

Asthma is thought to arise as a result of interactions between multiple genetic and environmental factors and is characterized by three major features: 1) intermittent and reversible airway obstruction caused by bronchoconstriction, increased mucus production, and thickening of the walls of the airways that leads to a narrowing of the airways, 2) airway hyperresponsiveness, and 3) airway inflammation. Certain cells are critical to the inflammatory reaction of asthma and they include T cells and antigen presenting cells, B cells that produce IgE, and mast cells, basophils, eosinophils, and other cells that bind IgE. These effector cells accumulate at the site of allergic reaction in the airways and release toxic products that contribute to the acute pathology and eventually to tissue destruction related to the disorder. Other resident cells, such as smooth muscle cells, lung epithelial cells, mucus-producing cells, and nerve cells may also be abnormal in individuals with asthma and may contribute to its pathology. While the airway obstruction of asthma, presenting clinically as an intermittent wheeze and shortness of breath, is generally the most pressing symptom of the disease requiring immediate treatment, the inflammation and tissue destruction associated with the disease can lead to irreversible changes that eventually make asthma a chronic and disabling disorder requiring long-term management.

Chronic obstructive pulmonary (or airways) disease (COPD) is a condition defined physiologically as airflow obstruction that generally results from a mixture of emphysema and peripheral airway obstruction due to chronic bronchitis [Botstein, 1980]. Emphysema is characterised by destruction of alveolar walls leading to abnormal enlargement of the air spaces of the lung. Chronic bronchitis is defined clinically as the presence of chronic productive cough for three months in each of two successive years. In COPD, airflow obstruction is usually progressive and is only partially reversible. By far the most important risk factor for development of COPD is cigarette smoking, although the disease does also occur in non-smokers.



5 The human EDG6 is highly expressed in the following tissues of the respiratory system: leukocytes (peripheral blood), bone marrow CD15+ cells, neutrophils cord blood, neutrophils peripheral blood, fetal lung, lung, lung right lower lobe, lung COPD, trachea, primary bronchia, secondary bronchia, bronchial epithelial cells, bronchial smooth muscle cells. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue lung COPD and healthy tissue lung demonstrates that the human EDG6 or mRNA can be utilized to diagnose of respiratory diseases. Additionally the activity of the human EDG6 can be  
10 modulated to treat those diseases.

*Disorders Related to Urology*

15 Genitourinary disorders comprise benign and malign disorders of the organs constituting the genitourinary system of female and male, renal diseases like acute or chronic renal failure, immunologically mediated renal diseases like renal transplant rejection, lupus nephritis, immune complex renal diseases, glomerulopathies, nephritis, toxic nephropathy, obstructive uropathies like benign prostatic hyperplasia (BPH), neurogenic bladder syndrome, urinary incontinence like urge-, stress-, or  
20 overflow incontinence, pelvic pain, and erectile dysfunction.

The human EDG6 is highly expressed in the following urological tissues: prostate tumor, ureter, penis. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue prostate tumor and healthy tissue  
25 prostate demonstrates that the human EDG6 or mRNA can be utilized to diagnose of urological disorders. Additionally the activity of the human EDG6 can be modulated to treat urological disorders.

*Applications*

The present invention provides for both prophylactic and therapeutic methods for cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases,  
5 hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma.

The regulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of EDG6. An agent that modulates activity  
10 can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of the polypeptide, a peptide, a peptidomimetic, or any small molecule. In one embodiment, the agent stimulates one or more of the biological activities of EDG6. Examples of such stimulatory agents include the active EDG6 and nucleic acid molecules encoding a portion of EDG6. In another  
15 embodiment, the agent inhibits one or more of the biological activities of EDG6. Examples of such inhibitory agents include antisense nucleic acid molecules and antibodies. These regulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g, by administering the agent to a subject). As such, the present invention provides methods of treating an individual  
20 afflicted with a disease or disorder characterized by unwanted expression or activity of EDG6 or a protein in the EDG6 signaling pathway. In one embodiment, the method involves administering an agent like any agent identified or being identifiable by a screening assay as described herein, or combination of such agents that modulate say upregulate or downregulate the expression or activity of EDG6 or  
25 of any protein in the EDG6 signaling pathway. In another embodiment, the method involves administering a regulator of EDG6 as therapy to compensate for reduced or undesirably low expression or activity of EDG6 or a protein in the EDG6 signaling pathway.

30 Stimulation of activity or expression of EDG6 is desirable in situations in which activity or expression is abnormally low and in which increased activity is likely to

have a beneficial effect. Conversely, inhibition of activity or expression of EDG6 is desirable in situations in which activity or expression of EDG6 is abnormally high and in which decreasing its activity is likely to have a beneficial effect.

5 This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are hereby incorporated by reference.

### **Pharmaceutical Compositions**

10

This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.

15

The nucleic acid molecules, polypeptides, and antibodies (also referred to herein as "active compounds") of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be

20

25

30

The invention includes pharmaceutical compositions comprising a regulator of EDG6 expression or activity (and/or a regulator of the activity or expression of a protein in the EDG6 signaling pathway) as well as methods for preparing such compositions by combining one or more such regulators and a pharmaceutically acceptable carrier. Also within the invention are pharmaceutical compositions

comprising a regulator identified using the screening assays of the invention packaged with instructions for use. For regulators that are antagonists of EDG6 activity or which reduce EDG6 expression, the instructions would specify use of the pharmaceutical composition for treatment of hematological and cardiovascular diseases, disorders of the peripheral and central nervous system, COPD, asthma, genito-urological disorders and inflammation diseases. For regulators that are agonists of EDG6 activity or increase EDG6 expression, the instructions would specify use of the pharmaceutical composition for treatment of hematological and cardiovascular diseases, disorders of the peripheral and central nervous system, COPD, asthma, genito-urological disorders and inflammation diseases.

An antagonist of EDG6 may be produced using methods which are generally known in the art. In particular, purified EDG6 may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind EDG6. Antibodies to EDG6 may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies like those which inhibit dimer formation are especially preferred for therapeutic use.

In another embodiment of the invention, the polynucleotides encoding EDG6, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding EDG6 may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding EDG6. Thus, complementary molecules or fragments may be used to modulate EDG6 activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding EDG6.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors which will express nucleic acid sequence complementary to the polynucleotides of the gene encoding EDG6. These techniques are described, for example, in [Scott and Smith (1990) Science 249:386-390].

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a pharmaceutical composition containing EDG6 in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of EDG6, antibodies to EDG6, and mimetics, agonists, antagonists, or inhibitors of EDG6. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants

such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EM<sup>TM</sup> (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, a pharmaceutically acceptable polyol like glycerol, propylene glycol, liquid polyethylene glycol, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol; sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin. Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a polypeptide or antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incor-

porating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed.

Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressurized container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile

salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

5

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

10

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.

15

Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. 4,522,811.

20

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

25

30



The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration. For pharmaceutical compositions which include an antagonist of EDG6 activity, a compound which reduces expression of EDG6, or a compound which reduces expression or activity of a protein in the EDG6 signaling pathway or any combination thereof, the instructions for administration will specify use of the composition for hematological and cardiovascular diseases, disorders of the peripheral and central nervous system, COPD, asthma, genito-urological disorders and inflammation diseases. For pharmaceutical compositions which include an agonist of EDG6 activity, a compound which increases expression of EDG6, or a compound which increases expression or activity of a protein in the EDG6 signaling pathway or any combination thereof, the instructions for administration will specify use of the composition for hematological and cardiovascular diseases, disorders of the peripheral and central nervous system, COPD, asthma, genito-urological disorders and inflammation diseases.

### Diagnostics

In another embodiment, antibodies which specifically bind EDG6 may be used for the diagnosis of disorders characterized by the expression of EDG6, or in assays to monitor patients being treated with EDG6 or agonists, antagonists, and inhibitors of EDG6. Antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for EDG6 include methods which utilize the antibody and a label to detect EDG6 in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent joining with a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring EDG6, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of

EDG6 expression. Normal or standard values for EDG6 expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to EDG6 under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, preferably by photometric means. Quantities of EDG6 expressed in subject samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding EDG6 may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of EDG6 may be correlated with disease. The diagnostic assay may be used to distinguish between absence, presence, and excess expression of EDG6, and to monitor regulation of EDG6 levels during therapeutic intervention.

Polynucleotide sequences encoding EDG6 may be used for the diagnosis of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma associated with expression of EDG6. The polynucleotide sequences encoding EDG6 may be used in Southern, Northern, or dot-blot analysis, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and ELISA assays; and in microarrays utilizing fluids or tissues from patient biopsies to detect altered EDG6 expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding EDG6 may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding EDG6 may be labelled by standard methods and added to a fluid or tissue sample from a patient under conditions

suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the patient sample is significantly altered from that of a comparable control sample, the nucleotide sequences have hybridized with nucleotide sequences in the sample, and the presence of altered levels of nucleotide sequences encoding EDG6 in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or in monitoring the treatment of an individual patient.

In order to provide a basis for the diagnosis of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma associated with expression of EDG6, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding EDG6, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained from normal samples may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO 84/03564. In this method, large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with EDG6, or fragments thereof, and washed. Bound EDG6 is then detected by methods well known in the art. Purified EDG6 can also be coated directly onto plates for use

in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

5 In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding EDG6 specifically compete with a testcompound for binding EDG6. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with EDG6.

10 G-protein coupled receptors are ubiquitous in the mammalian host and are responsible for many biological functions, including many pathologies. Accordingly, it is desirable to find compounds and drugs which stimulate a G-protein coupled receptor on the one hand and which can inhibit the function of a G-protein coupled receptor on the other hand. For example, compounds which activate the G-protein coupled receptor may be employed for therapeutic purposes, such as the treatment of  
15 asthma, Parkinson's disease, acute heart failure, urinary retention, and osteoporosis. In particular, compounds which activate the receptors of the present invention are useful in treating various cardiovascular ailments such as caused by the lack of pulmonary blood flow or hypertension. In addition these compounds may also be  
20 used in treating various physiological disorders relating to abnormal control of fluid and electrolyte homeostasis and in diseases associated with abnormal angiotensin-induced aldosterone secretion.

25 In general, compounds which inhibit activation of the G-protein coupled receptor may be employed for a variety of therapeutic purposes, for example, for the treatment of hypotension and/or hypertension, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders including schizophrenia, manic excitement, depression, delirium, dementia or severe mental retardation, dyskinesias, such as Huntington's disease or Tourett's  
30 syndrome, among others. Compounds which inhibit G-protein coupled receptors have also been useful in reversing endogenous anorexia and in the control of bulimia.

### **Determination of a Therapeutically Effective Dose**

5 The determination of a therapeutically effective dose is well within the capability of those skilled in the art. A therapeutically effective dose refers to that amount of active ingredient which increases or decreases EDG6 activity relative to EDG6 activity which occurs in the absence of the therapeutically effective dose. For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dogs, or pigs. The animal model also can be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

15 Therapeutic efficacy and toxicity, e.g., ED<sub>50</sub> (the dose therapeutically effective in 50% of the population) and LD<sub>50</sub> (the dose lethal to 50% of the population), can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD<sub>50</sub>/ED<sub>50</sub>. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED<sub>50</sub> with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration. The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active ingredient or to maintain the desired effect. Factors which can be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical com-

20  
25  
30

positions can be administered every 3 to 4 days, every week, or once every two weeks depending on the half-life and clearance rate of the particular formulation.

5 Normal dosage amounts can vary from 0.1 micrograms to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, 10 locations, etc. If the reagent is a single-chain antibody, polynucleotides encoding the antibody can be constructed and introduced into a cell either *ex vivo* or *in vivo* using well-established techniques including, but not limited to, transferrin-polycation-mediated DNA transfer, transfection with naked or encapsulated nucleic acids, liposome-mediated cellular fusion, intracellular transportation of DNA-coated latex beads, protoplast fusion, viral infection, electroporation, "gene gun", and DEAE- or 15 calcium phosphate-mediated transfection.

If the expression product is mRNA, the reagent is preferably an antisense oligonucleotide or a ribozyme. Polynucleotides which express antisense oligonucleotides or ribozymes can be introduced into cells by a variety of methods, as described 20 above. Preferably, a reagent reduces expression of EDG6 gene or the activity of EDG6 by at least about 10, preferably about 50, more preferably about 75, 90, or 100% relative to the absence of the reagent. The effectiveness of the mechanism chosen to decrease the level of expression of EDG6 gene or the activity of EDG6 can be assessed using methods well known in the art, such as hybridization of nucleotide 25 probes to EDG6-specific mRNA, quantitative RT-PCR, immunologic detection of EDG6, or measurement of EDG6 activity.

30 In any of the embodiments described above, any of the pharmaceutical compositions of the invention can be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination

therapy can be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents can act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects. Any of the therapeutic methods described above can be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

Nucleic acid molecules of the invention are those nucleic acid molecules which are contained in a group of nucleic acid molecules consisting of (i) nucleic acid molecules encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, (ii) nucleic acid molecules comprising the sequence of SEQ ID NO: 1, (iii) nucleic acid molecules having the sequence of SEQ ID NO: 1, (iv) nucleic acid molecules the complementary strand of which hybridizes under stringent conditions to a nucleic acid molecule of (i), (ii), or (iii); and (v) nucleic acid molecules the sequence of which differs from the sequence of a nucleic acid molecule of (iii) due to the degeneracy of the genetic code, wherein the polypeptide encoded by said nucleic acid molecule has EDG6 activity.

Polypeptides of the invention are those polypeptides which are contained in a group of polypeptides consisting of (i) polypeptides having the sequence of SEQ ID NO: 2, (ii) polypeptides comprising the sequence of SEQ ID NO: 2, (iii) polypeptides encoded by nucleic acid molecules of the invention and (iv) polypeptides which show at least 99%, 98%, 95%, 90%, or 80% homology with a polypeptide of (i), (ii), or (iii), wherein said purified polypeptide has EDG6 activity.

An object of the invention is a method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological

disorders, thrombocytopenia and myeloma in a mammal comprising the steps of (i) contacting a test compound with a EDG6 polypeptide, (ii) detect binding of said test compound to said EDG6 polypeptide. E.g., compounds that bind to the EDG6 polypeptide are identified potential therapeutic agents for such a disease.

5

Another object of the invention is a method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal comprising the steps of (i) determining the activity of a EDG6 polypeptide at a certain concentration of a test compound or in the absence of said test compound, (ii) determining the activity of said polypeptide at a different concentration of said test compound. E.g., compounds that lead to a difference in the activity of the EDG6 polypeptide in (i) and (ii) are identified potential therapeutic agents for such a disease.

15

Another object of the invention is a method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal comprising the steps of (i) determining the activity of a EDG6 polypeptide at a certain concentration of a test compound, (ii) determining the activity of a EDG6 polypeptide at the presence of a compound known to be a regulator of a EDG6 polypeptide. E.g., compounds that show similar effects on the activity of the EDG6 polypeptide in (i) as compared to compounds used in (ii) are identified potential therapeutic agents for such a disease.

20

25

Other objects of the invention are methods of the above, wherein the step of contacting is in or at the surface of a cell.

30

Other objects of the invention are methods of the above, wherein the cell is in vitro.



Other objects of the invention are methods of the above, wherein the step of contacting is in a cell-free system.

- 5 Other objects of the invention are methods of the above, wherein the polypeptide is coupled to a detectable label.

Other objects of the invention are methods of the above, wherein the compound is coupled to a detectable label.

10

Other objects of the invention are methods of the above, wherein the test compound displaces a ligand which is first bound to the polypeptide.

15

Other objects of the invention are methods of the above, wherein the polypeptide is attached to a solid support.

Other objects of the invention are methods of the above, wherein the compound is attached to a solid support.

20

Another object of the invention is a method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal comprising the steps of (i) contacting a test compound with a EDG6 polynucleotide, (ii) detect binding of said test compound to said EDG6 polynucleotide. Compounds that, e.g., bind to the EDG6 polynucleotide are potential therapeutic agents for the treatment of such diseases.

25

30

Another object of the invention is the method of the above, wherein the nucleic acid molecule is RNA.

Another object of the invention is a method of the above, wherein the contacting step is in or at the surface of a cell.

5 Another object of the invention is a method of the above, wherein the contacting step is in a cell-free system.

Another object of the invention is a method of the above, wherein the polynucleotide is coupled to a detectable label.

10

Another object of the invention is a method of the above, wherein the test compound is coupled to a detectable label.

15

Another object of the invention is a method of diagnosing a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal comprising the steps of (i) determining the amount of a EDG6 polynucleotide in a sample taken from said mammal, (ii) determining the amount of EDG6 polynucleotide in healthy and/or diseased mammal. A disease is diagnosed, e.g., if there is a substantial similarity in the amount of EDG6 polynucleotide in said test mammal as compared to a diseased mammal.

20

Another object of the invention is a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal comprising a therapeutic agent which binds to a EDG6 polypeptide.

25

30

Another object of the invention is a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal comprising a therapeutic agent which regulates the activity of a EDG6 polypeptide. ..

Another object of the invention is a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal comprising a therapeutic agent which regulates the activity of a EDG6 polypeptide, wherein said therapeutic agent is (i) a small molecule, (ii) an RNA molecule, (iii) an antisense oligonucleotide, (iv) a polypeptide, (v) an antibody, or (vi) a ribozyme.

Another object of the invention is a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal comprising a EDG6 polynucleotide.

Another object of the invention is a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal comprising a EDG6 polypeptide.

Another object of the invention is the use of regulators of a EDG6 for the preparation of a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases,

inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal.

5 Another object of the invention is a method for the preparation of a pharmaceutical composition useful for the treatment of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal comprising the steps of (i) identifying a regulator of EDG6, (ii) determining whether  
10 said regulator ameliorates the symptoms of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal; and (iii) combining of said regulator with an acceptable pharmaceutical carrier.

15 Another object of the invention is the use of a regulator of EDG6 for the regulation of EDG6 activity in a mammal having a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma.  
20

The examples below are provided to illustrate the subject invention. These examples are provided by way of illustration and are not included for the purpose of limiting the invention.

### Examples

#### **Example 1: Search for homologous sequences in public sequence data bases**

5 The degree of homology can readily be calculated by known methods. Preferred methods to determine homology are designed to give the largest match between the sequences tested. Methods to determine homology are codified in publicly available computer programs such as BestFit, BLASTP, BLASTN, and FASTA. The BLAST programs are publicly available from NCBI and other sources in the internet.

10

For EDG6 the following hits to known sequences were identified by using the BLAST algorithm [Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ; Nucleic Acids Res 1997 Sep 1; 25(17): 3389-402] and the following set of parameters: matrix = BLOSUM62 and low complexity filter. The following  
15 databases were searched: NCBI (non-redundant database) and DERWENT patent database (Geneseq).

The following hits were found:

20 >ref|NP\_003766.1| endothelial differentiation, G protein coupled receptor 6 precursor; putative G-protein coupled receptor [Homo sapiens] emb|CAA04118.1| putative G-Protein coupled receptor, EDG6 [Homo sapiens] gb|AAH14970.1|AAH14970 Unknown (protein for MGC:23096) [Homo sapiens] Length = 384 Score = 761 bits (1966), Expect = 0.0 Identities = 384/384 (100%),  
25 Positives = 384/384 (100%)

>ref|XP\_234930.1| similar to endothelial differentiation, G-protein-coupled receptor 6 [Mus musculus] [Rattus norvegicus] Length = 386 Score = 635 bits (1639), Expect = 0.0 Identities = 315/379 (83%), Positives = 344/379 (90%), Gaps = 2/379 (0%)

30

- >ref|NP\_034232.1| endothelial differentiation, G-protein-coupled receptor 6 [Mus musculus] emb|CAA06847.1| G protein-coupled receptor [Mus musculus] Length = 386 Score = 628 bits (1620), Expect = e-179 Identities = 314/379 (82%), Positives = 342/379 (89%), Gaps = 2/379 (0%)
- 5 >emb|CAD33254.1| sphingosine-1-phosphate G protein coupled receptor [Mus musculus] Length = 386 Score = 626 bits (1614), Expect = e-178 Identities = 313/379 (82%), Positives = 341/379 (89%), Gaps = 2/379 (0%)
- 10 >gb|AAE25057.1| Sequence 1 from patent US 5912144 Length = 509 Score = 552 bits (1423), Expect = e-156 Identities = 295/355 (83%), Positives = 300/355 (84%), Gaps = 11/355 (3%)
- >dbj|BAC36006.1| unnamed protein product [Mus musculus] Length = 318 Score = 541 bits (1393), Expect = e-153 Identities = 266/318 (83%), Positives = 293/318 (91%), Gaps = 1/318 (0%)
- 15 >gb|AAB44806.1| Sequence 4 from patent US 5585476 gb|AAE00838.1| Sequence 4 from patent US 5856443 Length = 383 Score = 255 bits (652), Expect = 7e-67 Identities = 139/334 (41%), Positives = 206/334 (61%), Gaps = 11/334 (3%)
- 20 >ref|NP\_058997.1| endothelial differentiation sphingolipid G-protein-coupled receptor 1 [Rattus norvegicus] sp|P48303|EDG1\_RAT PROBABLE G PROTEIN-COUPLED RECEPTOR EDG-1 pir||I53870 Edg-1 orphan receptor - rat gb|AAA83418.1| Edg-1 orphan receptor Length = 383 Score = 255 bits (652), Expect = 7e-67 Identities = 139/334 (41%), Positives = 206/334 (61%), Gaps = 11/334 (3%)
- 25 >gb|AAO30906.1| Sequence 2 from patent US 6323333 Length = 382 Score = 250 bits (639), Expect = 2e-65 Identities = 137/334 (41%), Positives = 202/334 (60%), Gaps = 11/334 (3%)
- 30

5 >ref|NP\_031927.2| endothelial differentiation sphingolipid G-protein-coupled  
receptor 1; endothelial differentiation gene 1 [Mus musculus] dbj|BAB23393.1|  
unnamed protein product [Mus musculus] Length = 382 Score = 250 bits (639),  
Expect = 2e-65 Identities = 137/334 (41%), Positives = 202/334 (60%), Gaps =  
11/334 (3%)

10 >pir|JC7559 sphingosine 1-phosphate receptor - zebra fish Length = 362 Score = 249  
bits (637), Expect = 4e-65 Identities = 148/345 (42%), Positives = 202/345 (57%),  
Gaps = 20/345 (5%)

>emb|CAC34036.1| unnamed protein product [Homo sapiens] gb|AAN99761.1|  
Sequence 22 from patent US 6485922 Length = 378 Score = 249 bits (636), Expect =  
5e-65 Identities = 141/333 (42%), Positives = 196/333 (58%), Gaps = 5/333 (1%)

15 >gb|AAE51663.1| Sequence 2 from patent US 6130067 Length = 378 Score = 249  
bits (636), Expect = 5e-65 Identities = 141/333 (42%), Positives = 196/333 (58%),  
Gaps = 5/333 (1%)

20 >ref|NP\_005217.1| endothelial differentiation, sphingolipid G-protein-coupled  
receptor, 3; G protein-coupled receptor, endothelial differentiation gene-3;  
lysosphingolipid receptor 3; sphingosine 1-phosphate receptor EDG3; S1P receptor  
EDG3 [Homo sapiens] sp|Q99500|EDG3\_HUMAN Lysosphingolipid receptor  
(EDG-3) pir|JC5245 G protein-coupled receptor - human emb|CAA58744.1| G-  
protein coupled receptor (putative) [Homo sapiens] gb|AAC51906.1|  
25 lysosphingolipid receptor [Homo sapiens] Length = 378 Score = 249 bits (636),  
Expect = 5e-65 Identitie

### Example 2: Expression profiling

30 Total cellular RNA was isolated from cells by one of two standard methods: 1)  
guanidine isothiocyanate/Cesium chloride density gradient centrifugation [Kellogg,

(1990)]; or with the Tri-Reagent protocol according to the manufacturer's specifications (Molecular Research Center, Inc., Cincinnati, Ohio). Total RNA prepared by the Tri-reagent protocol was treated with DNase I to remove genomic DNA contamination.

5

For relative quantitation of the mRNA distribution of EDG6, total RNA from each cell or tissue source was first reverse transcribed. 85 µg of total RNA was reverse transcribed using 1 µmole random hexamer primers, 0.5 mM each of dATP, dCTP, dGTP and dTTP (Qiagen, Hilden, Germany), 3000 U RnaseQut (Invitrogen, Groningen, Netherlands) in a final volume of 680 µl. The first strand synthesis buffer and Omniscript reverse transcriptase (2 u/µl) were from (Qiagen, Hilden, Germany). The reaction was incubated at 37°C for 90 minutes and cooled on ice. The volume was adjusted to 6800 µl with water, yielding a final concentration of 12.5 ng/µl of starting RNA.

15

For relative quantitation of the distribution of EDG6 mRNA in cells and tissues the Applied Biosystems 7900 HT Sequence Detection system or Biorad iCycler was used according to the manufacturer's specifications and protocols. PCR reactions were set up to quantitate EDG6 and the housekeeping genes HPRT (hypoxanthine phosphoribosyltransferase), GAPDH (glyceraldehyde-3-phosphate dehydrogenase), β-actin, and others. Forward and reverse primers and probes for EDG6 were designed using the Perkin Elmer ABI Primer Express™ software and were synthesized by TibMolBiol (Berlin, Germany). The EDG6 forward primer sequence was: Primer1 (SEQ ID NO: 3). The EDG6 reverse primer sequence was Primer2 (SEQ ID NO: 4). Probe1 (SEQ ID NO: 5), labelled with FAM (carboxyfluorescein succinimidyl ester) as the reporter dye and TAMRA (carboxytetramethylrhodamine) as the quencher, is used as a probe for EDG6. The following reagents were prepared in a total of 25 µl : 1x TaqMan buffer A, 5.5 mM MgCl<sub>2</sub>, 200 nM of dATP, dCTP, dGTP, and dUTP, 0.025 U/µl AmpliTaq Gold™, 0.01 U/ µl AmpErase and Probe1 (SEQ ID NO: 4), EDG6 forward and reverse primers each at 200 nM, 200 nM EDG6 FAM/TAMRA-labelled probe, and 5 µl of template cDNA. Thermal cycling

30



parameters were 2 min at 50°C, followed by 10 min at 95°C, followed by 40 cycles of melting at 95°C for 15 sec and annealing/extending at 60°C for 1 min.

### *Calculation of corrected CT values*

5

The CT (threshold cycle) value is calculated as described in the "Quantitative determination of nucleic acids" section. The CF-value (factor for threshold cycle correction) is calculated as follows :

10

1. PCR reactions were set up to quantitate the housekeeping genes (HKG) for each cDNA sample.

2.  $CT_{HKG}$ -values (threshold cycle for housekeeping gene) were calculated as described in the "Quantitative determination of nucleic acids" section.

15

3.  $CT_{HKG}$ -mean values (CT mean value of all HKG tested on one cDNAs) of all HKG for each cDNA are calculated ( $n$  = number of HKG):

$$CT_{HKG-n}\text{-mean value} = (CT_{HKG1}\text{-value} + CT_{HKG2}\text{-value} + \dots + CT_{HKG-n}\text{-value}) / n$$

20

4.  $CT_{\text{panel}}$  mean value (CT mean value of all HKG in all tested cDNAs) =

$$(CT_{HKG1}\text{-mean value} + CT_{HKG2}\text{-mean value} + \dots + CT_{HKG-y}\text{-mean value}) / y$$

( $y$  = number of cDNAs)

25

5.  $CF_{cDNA-n}$  (correction factor for cDNA  $n$ ) =  $CT_{\text{panel}}$ -mean value -  $CT_{HKG-n}$ -mean value

30

6.  $CT_{cDNA-n}$  (CT value of the tested gene for the cDNA  $n$ ) +  $CF_{cDNA-n}$  (correction factor for cDNA  $n$ ) =  $CT_{\text{cor-cDNA-n}}$  (corrected CT value for a gene on cDNA  $n$ )

*Calculation of relative expression*

Definition : highest  $CT_{\text{cor-cDNA-n}} \neq 40$  is defined as  $CT_{\text{cor-cDNA}} [\text{high}]$

Relative Expression =  $2^{(CT_{\text{cor-cDNA}}[\text{high}] - CT_{\text{cor-cDNA-n}})}$

5

*Tissues*

The expression of EDG6 was investigated in the tissues listed in table 1.

10 *Expression profile*

The results of the the mRNA-quantification (expression profiling) is shown in Table 1.

15 **Table 1:** *Relative expression of EDG6 in various human tissues*

	<u>Tissue</u>	<u>Relative Expression</u>
	fetal heart	29
20	heart	214
	pericardium	452
	heart atrium (right)	51
	heart atrium (left)	1060
	heart ventricle (left)	329
25	heart ventricle (right)	1
	heart apex	1
	Purkinje fibers	20
	interventricular septum	21
	fetal aorta	57
30	aorta	11
	artery	119
	coronary artery	7

	pulmonary artery	7
	carotid artery	8
	mesenteric artery	30
	vein	113
5	pulmonic valve	1121
	coronary artery smooth muscle primary cells	355
	aortic smooth muscle cells	10
	pulmonary artery smooth muscle cells	36
	aortic endothel cells	781
10	coronary artery endothel cells	1176
	HUVEC cells	97
	pulmonary artery endothel cells	3
	iliac artery endothel cells	70
15	skin	367
	adrenal gland	662
	thyroid	910
	thyroid tumor	134
20	pancreas	734
	pancreas liver cirrhosis	936
	esophagus	1144
	esophagus tumor	60
25	stomach	3743
	stomach tumor	254
	colon	465
	colon tumor	82
	small intestine	1820
30	ileum	1235
	ileum tumor	626
	ileum chronic inflammation	7804
	rectum	10514
	salivary gland	167

	fetal liver	729
	liver	217
	liver liver cirrhosis	21619
	liver lupus disease	1
5	liver tumor	148
	HEP G2 cells	41
	leukocytes (peripheral blood)	19484
	Jurkat (T-cells)	617
10	bone marrow	10809
	erythrocytes	2077
	lymphnode	584
	thymus	1846
	thrombocytes	564
15	bone marrow stromal cells	136
	bone marrow CD71+ cells	1710
	bone marrow CD33+ cells	1046
	bone marrow CD34+ cells	13034
	bone marrow CD15+ cells	15287
20	cord blood CD71+ cells	2288
	cord blood CD34+ cells	4939
	neutrophils cord blood	14563
	neutrophils peripheral blood	20595
	spleen	2937
25	spleen liver cirrhosis	40342
	skeletal muscle	234
	cartilage	265
	bone connective tissue	247
30	adipose	46
	fetal brain	115
	brain	635
	Alzheimer brain	3236

	cerebellum	265
	Alzheimer brain cerebellum	2195
	cerebellum (right)	64
	cerebellum (left)	331
5	cerebral cortex	75
	Alzheimer cerebral cortex	1499
	frontal lobe	168
	Alzheimer brain frontal lobe	199
	occipital lobe	431
10	parietal lobe	241
	temporal lobe	50
	postcentral gyrus	205
	vermis cerebelli	64
	pons	13
15	substantia nigra	197
	caudatum	169
	cerebral meninges	8
	cerebral peduncles	161
	corpus callosum	237
20	nucleus accumbens	61
	putamen	119
	hippocampus	657
	thalamus	452
	posteroventral thalamus	2896
25	dorsalmedial thalamus	4804
	hypothalamus	83
	dorsal root ganglia	4
	spinal cord	580
	spinal cord (ventral horn)	4513
30	spinal cord (dorsal horn)	12077
	neuroblastoma SK-N-MC cells	72
	neuroblastoma SH-SY5Y cells	695
	neuroblastoma IMR32 cells	3304
	glial tumor H4 cells	596

	HEK CNS + APP	891
	neural progenitor cells	936
	astrocytes	1531
	retina	465
5	fetal lung	2385
	fetal lung fibroblast IMR-90 cells	1
	fetal lung fibroblast MRC-5 cells	7
	lung	5367
10	lung right upper lobe	662
	lung right mid lobe	917
	lung right lower lobe	2557
	lung lupus disease	111
	lung tumor	458
15	lung COPD	1898
	trachea	3126
	primary bronchia	4360
	secondary bronchia	4673
	bronchial epithelial cells	1296
20	bronchial smooth muscle cells	1641
	small airway epithelial cells	62
	cervix	155
	testis	180
25	HeLa cells (cervix tumor)	14
	placenta	271
	uterus	41
	uterus tumor	36
	ovary	304
30	ovary tumor	290
	breast	169
	breast tumor	4211
	MDA MB 231 cells (breast tumor)	3
	mammary gland	181

	prostate	350
	prostate BPH	185
	prostate tumor	3169
5	bladder	431
	ureter	4270
	penis	5673
	corpus cavernosum	263
	fetal kidney	61
10	kidney	91
	kidney tumor	150
	renal epithelial cells	69
	HEK 293 cells	32

### 15 **Example 3: Antisense Analysis**

Knowledge of the correct, complete cDNA sequence coding for EDG6 enables its use as a tool for antisense technology in the investigation of gene function. Oligonucleotides, cDNA or genomic fragments comprising the antisense strand of a polynucleotide coding for EDG6 are used either in vitro or in vivo to inhibit translation of the mRNA. Such technology is now well known in the art, and antisense molecules can be designed at various locations along the nucleotide sequences. By treatment of cells or whole test animals with such antisense sequences, the gene of interest is effectively turned off. Frequently, the function of the gene is ascertained by observing behavior at the intracellular, cellular, tissue or organismal level (e.g., lethality, loss of differentiated function, changes in morphology, etc.).

In addition to using sequences constructed to interrupt transcription of a particular open reading frame, modifications of gene expression is obtained by designing antisense sequences to intron regions, promoter/enhancer elements, or even to trans-acting regulatory genes.

**Example 4: Expression of EDG6**

5 Expression of EDG6 is accomplished by subcloning the cDNAs into appropriate expression vectors and transfecting the vectors into expression hosts such as, e.g., *E. coli*. In a particular case, the vector is engineered such that it contains a promoter for  $\beta$ -galactosidase, upstream of the cloning site, followed by sequence containing the amino-terminal Methionine and the subsequent seven residues of  $\beta$ -galactosidase. Immediately following these eight residues is an engineered bacteriophage promoter  
10 useful for artificial priming and transcription and for providing a number of unique endonuclease restriction sites for cloning.

Induction of the isolated, transfected bacterial strain with Isopropyl- $\beta$ -D-thio-  
15 galactopyranoside (IPTG) using standard methods produces a fusion protein corresponding to the first seven residues of  $\beta$ -galactosidase, about 15 residues of "linker", and the peptide encoded within the cDNA. Since cDNA clone inserts are generated by an essentially random process, there is probability of 33% that the included cDNA will lie in the correct reading frame for proper translation. If the cDNA is not in the proper reading frame, it is obtained by deletion or insertion of the  
20 appropriate number of bases using well known methods including in vitro mutagenesis, digestion with exonuclease III or mung bean nuclease, or the inclusion of an oligonucleotide linker of appropriate length.

25 The EDG6 cDNA is shuttled into other vectors known to be useful for expression of proteins in specific hosts. Oligonucleotide primers containing cloning sites as well as a segment of DNA (about 25 bases) sufficient to hybridize to stretches at both ends of the target cDNA is synthesized chemically by standard methods. These primers are then used to amplify the desired gene segment by PCR. The resulting gene segment is digested with appropriate restriction enzymes under standard  
30 conditions and isolated by gel electrophoresis. Alternately, similar gene segments are produced by digestion of the cDNA with appropriate restriction enzymes. Using



appropriate primers, segments of coding sequence from more than one gene are ligated together and cloned in appropriate vectors. It is possible to optimize expression by construction of such chimeric sequences.

5 Suitable expression hosts for such chimeric molecules include, but are not limited to, mammalian cells such as Chinese Hamster Ovary (CHO) and human 293 cells., insect cells such as Sf9 cells, yeast cells such as *Saccharomyces cerevisiae* and bacterial cells such as *E. coli*. For each of these cell systems, a useful expression vector also includes an origin of replication to allow propagation in bacteria, and a  
10 selectable marker such as the  $\beta$ -lactamase antibiotic resistance gene to allow plasmid selection in bacteria. In addition, the vector may include a second selectable marker such as the neomycin phosphotransferase gene to allow selection in transfected eukaryotic host cells. Vectors for use in eukaryotic expression hosts require RNA processing elements such as 3' polyadenylation sequences if such are not part of the  
15 cDNA of interest.

Additionally, the vector contains promoters or enhancers which increase gene expression. Such promoters are host specific and include MMTV, SV40, and metallothionine promoters for CHO cells; trp, lac, tac and T7 promoters for bacterial  
20 hosts; and alpha factor, alcohol oxidase and PGH promoters for yeast. Transcription enhancers, such as the rous sarcoma virus enhancer, are used in mammalian host cells. Once homogeneous cultures of recombinant cells are obtained through standard culture methods, large quantities of recombinantly produced EDG6 are recovered from the conditioned medium and analyzed using chromatographic  
25 methods known in the art. For example, EDG6 can be cloned into the expression vector pcDNA3, as exemplified herein. This product can be used to transform, for example, HEK293 or COS by methodology standard in the art. Specifically, for example, using Lipofectamine (Gibco BRL catalog no. 18324-020) mediated gene transfer.

**Example 5: Isolation of Recombinant EDG6**

EDG6 is expressed as a chimeric protein with one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals [Appa Rao, 1997] and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Washington). The inclusion of a cleavable linker sequence such as Factor Xa or enterokinase (Invitrogen, Groningen, The Netherlands) between the purification domain and the EDG6 sequence is useful to facilitate expression of EDG6.

**Example 6: Testing of Chimeric GPCRs**

Functional chimeric GPCRs are constructed by combining the extracellular receptive sequences of a new isoform with the transmembrane and intracellular segments of a known isoform for test purposes. This concept was demonstrated by Kobilka et al. (1988), Science 240:1310-1316) who created a series of chimeric  $\alpha 2$ - $\beta 2$  adrenergic receptors (AR) by inserting progressively greater amounts of  $\alpha 2$ -AR transmembrane sequence into  $\beta 2$ -AR. The binding activity of known agonists changed as the molecule shifted from having more  $\alpha 2$  than  $\beta 2$  conformation, and intermediate constructs demonstrated mixed specificity. The specificity for binding antagonists, however, correlated with the source of the domain VII. The importance of T7G domain VII for ligand recognition was also found in chimeras utilizing two yeast  $\alpha$ -factor receptors and is significant because the yeast receptors are classified as miscellaneous receptors. Thus, functional role of specific domains appears to be preserved throughout the GPCR family regardless of category.

In parallel fashion, internal segments or cytoplasmic domains from a particular isoform are exchanged with the analogous domains of a known GPCRs and used to identify the structural determinants responsible for coupling the receptors to trimeric

G-proteins. A chimeric receptor in which domains V, VI, and the intracellular connecting loop from  $\beta$ 2-AR were substituted into  $\alpha$ 2-AR was shown to bind ligands with  $\alpha$ 2-AR specificity, but to stimulate adenylate cyclase in the manner of  $\beta$ 2-AR. This demonstrates that for adrenergic-type receptors, G-protein recognition is present in domains V and VI and their connecting loop. The opposite situation was predicted and observed for a chimera in which the V->VI loop from  $\alpha$ 1-AR replaced the corresponding domain on  $\beta$ 2-AR and the resulting receptor bound ligands with  $\beta$ 2-AR specificity and activated G-protein-mediated phosphatidylinositol turnover in the  $\alpha$ 1-AR manner. Finally, chimeras constructed from muscarinic receptors also demonstrated that V->VI loop is the major determinant for specificity of G-protein activity.

Chimeric or modified GPCRs containing substitutions in the extracellular and transmembrane regions have shown that these portions of the receptor determine ligand binding specificity. For example, two Serine residues conserved in domain V of all adrenergic and D catecholamine GPCRs are necessary for potent agonist activity. These serines are believed to form hydrogen bonds with the catechol moiety of the agonists within the GPCR binding site. Similarly, an Asp residue present in domain III of all GPCRs which bind biogenic amines is believed to form an ion pair with the ligand amine group in the GPCR binding site.

Functional, cloned GPCRs are expressed in heterologous expression systems and their biological activity assessed. One heterologous system introduces genes for a mammalian GPCR and a mammalian G-protein into yeast cells. The GPCR is shown to have appropriate ligand specificity and affinity and trigger appropriate biological activation (growth arrest and morphological changes) of the yeast cells.

An alternate procedure for testing chimeric receptors is based on the procedure utilizing the purinergic receptor ( $P_{2u}$ ). Function is easily tested in cultured K562 human leukemia cells because these cells lack  $P_{2u}$  receptors. K562 cells are transfected with expression vectors containing either normal or chimeric  $P_{2u}$  and

loaded with fura-a, fluorescent probe for  $\text{Ca}^{++}$ . Activation of properly assembled and functional  $\text{P}_2\text{u}$  receptors with extracellular UTP or ATP mobilizes intracellular  $\text{Ca}^{++}$  which reacts with fura-a and is measured spectrofluorometrically.

5 As with the GPCRs above, chimeric genes are created by combining sequences for extracellular receptive segments of any new GPCR polypeptide with the nucleotides for the transmembrane and intracellular segments of the known  $\text{P}_2\text{u}$  molecule. Bathing the transfected K562 cells in microwells containing appropriate ligands triggers binding and fluorescent activity defining effectors of the GPCR molecule.  
10 Once ligand and function are established, the  $\text{P}_2\text{u}$  system is useful for defining antagonists or inhibitors which block binding and prevent such fluorescent reactions.

#### **Example 7: Production of EDG6 Specific Antibodies**

15 Two approaches are utilized to raise antibodies to EDG6, and each approach is useful for generating either polyclonal or monoclonal antibodies. In one approach, denatured protein from reverse phase HPLC separation is obtained in quantities up to 75 mg. This denatured protein is used to immunize mice or rabbits using standard protocols; about 100  $\mu\text{g}$  are adequate for immunization of a mouse, while up to 1 mg  
20 might be used to immunize a rabbit. For identifying mouse hybridomas, the denatured protein is radioiodinated and used to screen potential murine B-cell hybridomas for those which produce antibody. This procedure requires only small quantities of protein, such that 20 mg is sufficient for labeling and screening of several thousand clones.

25 In the second approach, the amino acid sequence of an appropriate EDG6 domain, as deduced from translation of the cDNA, is analyzed to determine regions of high antigenicity. Oligopeptides comprising appropriate hydrophilic regions are synthesized and used in suitable immunization protocols to raise antibodies. The  
30 optimal amino acid sequences for immunization are usually at the C-terminus, the N-terminus and those intervening, hydrophilic regions of the polypeptide which are

likely to be exposed to the external environment when the protein is in its natural conformation.

Typically, selected peptides, about 15 residues in length, are synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry and coupled to keyhole limpet hemocyanin (KLH; Sigma, St. Louis, MO) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester, MBS. If necessary, a cysteine is introduced at the N-terminus of the peptide to permit coupling to KLH. Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity by binding the peptide to plastic, blocking with 1% bovine serum albumin, reacting with antisera, washing and reacting with labeled (radioactive or fluorescent), affinity purified, specific goat anti-rabbit IgG.

Hybridomas are prepared and screened using standard techniques. Hybridomas of interest are detected by screening with labeled EDG6 to identify those fusions producing the monoclonal antibody with the desired specificity. In a typical protocol, wells of plates (FAST; Becton-Dickinson, Palo Alto, CA) are coated during incubation with affinity purified, specific rabbit anti-mouse (or suitable antispecies 1 g) antibodies at 10 mg/ml. The coated wells are blocked with 1% bovine serum albumin, (BSA), washed and incubated with supernatants from hybridomas. After washing the wells are incubated with labeled EDG6 at 1 mg/ml. Supernatants with specific antibodies bind more labeled EDG6 than is detectable in the background. Then clones producing specific antibodies are expanded and subjected to two cycles of cloning at limiting dilution. Cloned hybridomas are injected into pristane-treated mice to produce ascites, and monoclonal antibody is purified from mouse ascitic fluid by affinity chromatography on Protein A. Monoclonal antibodies with affinities of at least

$10^8 \text{ M}^{-1}$ , preferably  $10^9$  to  $10^{10} \text{ M}^{-1}$  or stronger, are typically made by standard procedures.

**Example 8: Diagnostic Test Using EDG6 Specific Antibodies**

5 Particular EDG6 antibodies are useful for investigating signal transduction and the diagnosis of infectious or hereditary conditions which are characterized by differences in the amount or distribution of EDG6 or downstream products of an active signaling cascade.

10 Diagnostic tests for EDG6 include methods utilizing antibody and a label to detect EDG6 in human body fluids, membranes, cells, tissues or extracts of such. The polypeptides and antibodies of the present invention are used with or without modification. Frequently, the polypeptides and antibodies are labeled by joining them, either covalently or noncovalently, with a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known  
15 and have been reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent agents, chemiluminescent agents, chromogenic agents, magnetic particles and the like.

20 A variety of protocols for measuring soluble or membrane-bound EDG6, using either polyclonal or monoclonal antibodies specific for the protein, are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering  
25 epitopes on EDG6 is preferred, but a competitive binding assay may be employed.

**Example 9: Purification of Native EDG6 Using Specific Antibodies**

Native or recombinant EDG6 is purified by immunoaffinity chromatography using antibodies specific for EDG6. In general, an immunoaffinity column is constructed by covalently coupling the anti-TRH antibody to an activated chromatographic resin.

Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway N.J.). Likewise, monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A. Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated Sepharose (Pharmacia LKB Biotechnology). The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturer's instructions.

Such immunoaffinity columns are utilized in the purification of EDG6 by preparing a fraction from cells containing EDG6 in a soluble form. This preparation is derived by solubilization of whole cells or of a subcellular fraction obtained via differential centrifugation (with or without addition of detergent) or by other methods well known in the art. Alternatively, soluble EDG6 containing a signal sequence is secreted in useful quantity into the medium in which the cells are grown.

A soluble EDG6-containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of EDG6 (e.g., high ionic strength buffers in the presence of detergent). Then, the column is eluted under conditions that disrupt antibody/protein binding (e.g., a buffer of pH 2-3 or a high concentration of a chaotrope such as urea or thiocyanate ion), and EDG6 is collected.

**Example 10: Drug Screening**

This invention is particularly useful for screening therapeutic compounds by using EDG6 or binding fragments thereof in any of a variety of drug screening techniques.

5. As EDG6 is a G protein coupled receptor any of the methods commonly used in the art may potentially be used to identify EDG6 ligands. For example, the activity of a G protein coupled receptor such as EDG6 can be measured using any of a variety of appropriate functional assays in which activation of the receptor results in an observable change in the level of some second messenger system, such as adenylate cyclase, guanylylcyclase, calcium mobilization, or inositol phospholipid hydrolysis. 10 Alternatively, the polypeptide or fragment employed in such a test is either free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or 15 fragment. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, are used for standard binding assays.

Measured, for example, is the formation of complexes between EDG6 and the agent 20 being tested. Alternatively, one examines the diminution in complex formation between EDG6 and a ligand caused by the agent being tested.

Thus, the present invention provides methods of screening for drug candidates, drugs, or any other agents which affect signal transduction. These methods, well known in 25 the art, comprise contacting such an agent with EDG6 polypeptide or a fragment thereof and assaying (i) for the presence of a complex between the agent and EDG6 polypeptide or fragment, or (ii) for the presence of a complex between EDG6 polypeptide or fragment and the cell. In such competitive binding assays, the EDG6 polypeptide or fragment is typically labeled. After suitable incubation, free EDG6 30 polypeptide or fragment is separated from that present in bound form, and the



amount of free or uncomplexed label is a measure of the ability of the particular agent to bind to EDG6 or to interfere with the EDG6-agent complex.

5 Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to EDG6 polypeptides. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with EDG6 polypeptide and washed. Bound EDG6 polypeptide is then detected by methods well known in the art. Purified EDG6 are also coated directly  
10 onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies are used to capture the peptide and immobilize it on the solid support.

15 This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding EDG6 specifically compete with a test compound for binding to EDG6 polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic determinants with EDG6.

#### 20 **Example 11: Rational Drug Design**

The goal of rational drug design is to produce structural analogs of biologically active polypeptides of interest or of small molecules with which they interact, agonists, antagonists, or inhibitors. Any of these examples are used to fashion drugs  
25 which are more active or stable forms of the polypeptide or which enhance or interfere with the function of a polypeptide in vivo.

In one approach, the three-dimensional structure of a protein of interest, or of a protein-inhibitor complex, is determined by x-ray crystallography, by computer  
30 modeling or, most typically, by a combination of the two approaches. Both the shape and charges of the polypeptide must be ascertained to elucidate the structure and to

determine active site(s) of the molecule. Less often, useful information regarding the structure of a polypeptide is gained by modeling based on the structure of homologous proteins. In both cases, relevant structural information is used to design efficient inhibitors. Useful examples of rational drug design include molecules which have improved activity or stability or which act as inhibitors, agonists, or antagonists of native peptides.

It is also possible to isolate a target-specific antibody, selected by functional assay, as described above, and then to solve its crystal structure. This approach, in principle, yields a pharmacore upon which subsequent drug design is based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-ids is expected to be an analog of the original receptor. The anti-id is then used to identify and isolate peptides from banks of chemically or biologically produced peptides. The isolated peptides then act as the pharmacore.

By virtue of the present invention, sufficient amount of polypeptide are made available to perform such analytical studies as X-ray crystallography. In addition, knowledge of the EDG6 amino acid sequence provided herein provides guidance to those employing computer modeling techniques in place of or in addition to x-ray crystallography.

#### **Example 12: Identification of Other Members of the Signal Transduction Complex**

The inventive purified EDG6 is a research tool for identification, characterization and purification of interacting G or other signal transduction pathway proteins. Radioactive labels are incorporated into a selected EDG6 domain by various methods known in the art and used in vitro to capture interacting molecules. A preferred method involves labeling the primary amino groups in EDG6 with <sup>125</sup>I Bolton-Hunter

reagent. This reagent has been used to label various molecules without concomitant loss of biological activity.

5 Labeled EDG6 is useful as a reagent for the purification of molecules with which it interacts. In one embodiment of affinity purification, membrane-bound EDG6 is covalently coupled to a chromatography column. Cell-free extract derived from synovial cells or putative target cells is passed over the column, and molecules with appropriate affinity bind to EDG6. EDG6-complex is recovered from the column, and the EDG6-binding ligand disassociated and subjected to N-terminal protein  
10 sequencing. The amino acid sequence information is then used to identify the captured molecule or to design degenerate oligonucleotide probes for cloning the relevant gene from an appropriate cDNA library.

15 In an alternate method, antibodies are raised against EDG6, specifically monoclonal antibodies. The monoclonal antibodies are screened to identify those which inhibit the binding of labeled EDG6. These monoclonal antibodies are then used therapeutically.

20 **Example 13: Use and Administration of Antibodies, Inhibitors, or Antagonists**

Antibodies, inhibitors, or antagonists of EDG6 or other treatments and compounds that are limiters of signal transduction (LSTs), provide different effects when administered therapeutically. LSTs are formulated in a nontoxic, inert, pharmaceutically acceptable aqueous carrier medium preferably at a pH of about 5 to 8,  
25 more preferably 6 to 8, although pH may vary according to the characteristics of the antibody, inhibitor, or antagonist being formulated and the condition to be treated. Characteristics of LSTs include solubility of the molecule, its half-life and antigenicity/immunogenicity. These and other characteristics aid in defining an effective carrier. Native human proteins are preferred as LSTs, but organic or  
30 synthetic molecules resulting from drug screens are equally effective in particular situations.

LSTs are delivered by known routes of administration including but not limited to topical creams and gels; transmucosal spray and aerosol; transdermal patch and bandage; injectable, intravenous and lavage formulations; and orally administered liquids and pills particularly formulated to resist stomach acid and enzymes. The particular formulation, exact dosage, and route of administration is determined by the attending physician and varies according to each specific situation.

Such determinations are made by considering multiple variables such as the condition to be treated, the LST to be administered, and the pharmacokinetic profile of a particular LST. Additional factors which are taken into account include severity of the disease state, patient's age, weight, gender and diet, time and frequency of LST administration, possible combination with other drugs, reaction sensitivities, and tolerance/response to therapy. Long acting LST formulations might be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular LST.

Normal dosage amounts vary from 0.1 to  $10^5$   $\mu$ g, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature; see U.S. Pat. Nos. 4,657,760; 5,206,344; or 5,225,212. Those skilled in the art employ different formulations for different LSTs. Administration to cells such as nerve cells necessitates delivery in a manner different from that to other cells such as vascular endothelial cells.

It is contemplated that abnormal signal transduction, trauma, or diseases which trigger EDG6 activity are treatable with LSTs. These conditions or diseases are specifically diagnosed by the tests discussed above, and such testing should be performed in suspected cases of viral, bacterial or fungal infections, allergic responses, mechanical injury associated with trauma, hereditary diseases, lymphoma or carcinoma, or other conditions which activate the genes of lymphoid or neuronal tissues.

**Example 14: Production of Non-human Transgenic Animals**

Animal model systems which elucidate the physiological and behavioral roles of the  
5 EDG6 are produced by creating nonhuman transgenic animals in which the activity  
of the EDG6 is either increased or decreased, or the amino acid sequence of the  
expressed EDG6 is altered, by a variety of techniques. Examples of these techniques  
include, but are not limited to: 1) Insertion of normal or mutant versions of DNA  
10 encoding a EDG6, by microinjection, electroporation, retroviral transfection or other  
means well known to those skilled in the art, into appropriately fertilized embryos in  
order to produce a transgenic animal or 2) homologous recombination of mutant or  
normal, human or animal versions of these genes with the native gene locus in  
transgenic animals to alter the regulation of expression or the structure of these  
15 EDG6 sequences. The technique of homologous recombination is well known in the  
art. It replaces the native gene with the inserted gene and hence is useful for  
producing an animal that cannot express native EDG6s but does express, for  
example, an inserted mutant EDG6, which has replaced the native EDG6 in the  
animal's genome by recombination, resulting in underexpression of the transporter.  
Microinjection adds genes to the genome, but does not remove them, and the  
20 technique is useful for producing an animal which expresses its own and added  
EDG6, resulting in overexpression of the EDG6.

One means available for producing a transgenic animal, with a mouse as an example,  
is as follows: Female mice are mated, and the resulting fertilized eggs are dissected  
25 out of their oviducts. The eggs are stored in an appropriate medium such as  
cesiumchloride M2 medium. DNA or cDNA encoding EDG6 is purified from a  
vector by methods well known to the one skilled in the art. Inducible promoters may  
be fused with the coding region of the DNA to provide an experimental means to  
regulate expression of the transgene. Alternatively or in addition, tissue specific  
30 regulatory elements may be fused with the coding region to permit tissue-specific  
expression of the transgene. The DNA, in an appropriately buffered solution, is put

into a microinjection needle (which may be made from capillary tubing using a piper puller) and the egg to be injected is put in a depression slide. The needle is inserted into the pronucleus of the egg, and the DNA solution is injected. The injected egg is then transferred into the oviduct of a pseudopregnant mouse which is a mouse stimulated by the appropriate hormones in order to maintain false pregnancy, where it proceeds to the uterus, implants, and develops to term. As noted above, microinjection is not the only method for inserting DNA into the egg but is used here only for exemplary purposes.

#### **Example 15: S1P Effects on Megakaryocyte Development**

Platelets are produced from megakaryocytes that are derived from CD34<sup>+</sup> progenitors in the bone marrow. During the development, ploidy of the megakaryocytes increases by endomitosis, and cytoplasmic compartments mature to gain a large number of secretory granules. The mature megakaryocytes extend cytoplasmic projections, the platelet processes, through holes in the endothelial barrier of an adjacent blood sinus, and bud off platelet particles into the circulation. Some mature megakaryocytes travel from the bone marrow to the lung where they are trapped in the microvasculature and release platelets. Discovery of thrombopoietin (TPO), the key factor regulating megakaryopoiesis, has led to a better understanding of the mechanisms of cellular differentiation in this cell lineage. However, a comprehensive understanding of the molecular mechanisms that regulate cytoplasmic development and platelet release remains obscure. Platelets released into the circulation play central roles in hemostasis. The activated platelets serve as plugs and secrete granules that initiate wound healing. It has been reported that platelets are the major storage site of the pleiotropic lipid signaling molecule, S1P. Upon activation, platelets release the constituents of their cytoplasm, including S1P, in conjunction with secretory granules thereby exerting a wide range of physiological actions. Five G protein-coupled receptors (GPCRs), S1P<sub>1</sub> (EDG-1), S1P<sub>2</sub> (EDG-5), S1P<sub>3</sub> (EDG-3), S1P<sub>4</sub> (EDG-6), and S1P<sub>5</sub> (EDG-8), have been identified as high affinity receptors for S1P in mammals. S1P exerts a variety of responses by activating a distinct set of G

proteins coupled to the S1P receptors in different types of cells. Of particular interest is the fact that S1P receptors are important for the development and maintenance of the vascular/circulatory system. Although platelets are not the constituents of vasculatures, they are the key regulators of S1P levels in the circulation. We were therefore curious whether S1P is involved in the regulation of megakaryopoiesis and subsequent release of platelets.

S1P was added to a megakaryocyte colony formation assay using CD34<sup>+</sup> hematopoietic progenitor cells in semi-solid culture. Addition of 10  $\mu$ M S1P at the beginning of the culture significantly reduced the number of megakaryocyte colony forming units (CFU-MK) of CD34<sup>+</sup> progenitor cells both from bone marrow and cord blood (Fig. 6A). In contrast, CFU-nonMK numbers remained unchanged or increased slightly. The results indicated that even in an environment that supports megakaryopoiesis, addition of S1P at an early stage of CD34<sup>+</sup> progenitor culture selectively suppresses the development of megakaryocytes. In order to examine the expression pattern of each S1P receptor during the *in vitro* maturation of megakaryocytes, CD34<sup>+</sup> progenitor cells were cultured in a liquid medium defined for megakaryocyte development, sorted for CD41 expression on day 12 of the culture, and subjected to RT-PCR analysis. Expression of S1P<sub>5</sub> receptor in CD34<sup>+</sup> cells on day 0 was low and S1P<sub>1</sub>, S1P<sub>2</sub>, S1P<sub>3</sub>, and EDG6 were not detectable after 40 cycles (Fig. 6B). After induction of differentiation for 12 days, robust EDG6, moderate S1P<sub>2</sub>, and low S1P<sub>1</sub> and S1P<sub>5</sub> expression was seen in the CD41<sup>+</sup> megakaryocyte population. The pattern matched, although with different relative band intensities for EDG6 and S1P<sub>2</sub>, with the one seen in the platelet sample. Notably, a distinct set of receptors, S1P<sub>1</sub> and S1P<sub>3</sub>, was predominant in the unsorted cell population compared to the CD41<sup>+</sup> cells. The observation suggested a lineage selective induction of distinct receptors for S1P, which may account for the different effects of S1P on CFU-MK and CFU-nonMK in the colony formation assay. The exact mechanisms by which S1P affects the differentiation however, remain to be elucidated. Among the receptors for S1P, we were most interested in the function of EDG6 in megakaryocytopoiesis, because EDG6 is expressed in the lung, and the

lung is the second most prominent site of platelet production in body with a large population of terminally differentiated megakaryocytes in pulmonary microvessels. As EDG6 was the most intensely expressed S1P receptor in CD41<sup>+</sup> cells, we hypothesized that EDG6 plays a role in the late phase development and maturation of megakaryocytes.

These data strongly support a crucial role of EDG6 in hematological processes.

#### **Example 16: EDG6 Mediated HEL Differentiation to Megakaryocyte-Like Cells**

Since a human erythroleukemia HEL 92.1.7 (HEL, ATCC# TIB-180) is known to differentiate to macrophage-like or to megakaryocyte-like cells with phorbol ester treatment, we transfected HEL cells with an expression vector encoding HA-tagged human EDG6 (HEL/EDG6) to determine whether this receptor could influence differentiation. The stable clones were obtained and maintained in RPMI medium containing 10 % FBS which would give an S1P concentration of about 30 nM. The clones revealed sporadic development of cell populations with increased cell volume having adherent and polyploid characteristics. Anti-HA immunostaining showed that such cells expressed EDG6 (data not shown). The surface expression of CD41 (GPIIb/IIIa), a platelet-megakaryocyte marker, was increased in the HEL/EDG6 cells without phorbol ester treatment, suggesting that there were cell populations differentiated to the megakaryocyte lineage (data not shown).

During propagation of HEL/EDG6, we observed an accumulation of small particles in the culture supernatant. They were harvested by two-step sedimentation centrifugation and analyzed. Immunostaining revealed that they were CD41-positive (data not shown) and the particles appeared to be platelet-like. In order to investigate if the platelet-like particles were functional, they were stimulated and the release of Platelet Factor IV (PF4) was measured as a platelet functional marker. The HEL/EDG6 particles released significant amounts of PF4 in response to thrombin



and PMA but only minor amounts to ADP (data not shown). The low sensitivity to ADP raised a question about the full functionality of the particles as platelets. In order to examine whether it is due to lack of the appropriate ADP receptors, we performed RT-PCR analysis. There are two ADP receptors identified in platelets, ubiquitous P2Y<sub>1</sub> and platelet-specific P2Y<sub>12</sub>. We detected P2Y<sub>1</sub> expression in HEL cells stably transformed with an empty vector (HEL/CV), HEL/EDG6, and platelets. In contrast, P2Y<sub>12</sub> was detected in HEL/EDG6 and platelets, but not in HEL/CV. This result indicated that the expression of platelet-specific P2Y<sub>12</sub> was induced by introduction of EDG6 into HEL cells, further supporting their phenotypic characterization as megakaryocytic. It is reasonable to assume that the platelet-like particles, fragmented from the cell bodies of HEL/EDG6, have the same ADP-receptors as seen on platelets. The low responsiveness of the particles to ADP thus is likely due to desensitization of the ADP receptors, since the particles were prepared from a long-term culture and had been inevitably exposed to cellular components during culture. Alternatively the density of the particles may not have been high enough to exert a positive feedback amplified by mediators released from nearby particles.

Compared to the spontaneous morphology change during normal culture, PMA-treatment of HEL/EDG6 showed a much more striking morphogenesis at 72 hours. As reported, HEL parental cells develop into polyploid large adherent cells with PMA treatment. In contrast, PMA treatment of HEL/EDG6 resulted in the formation of polyploid large adherent cells with extended cytoplasmic projections resembling megakaryocyte processes. Depositions of small particles and particles about to bud off from the end of the projections were also observed (Fig. 7). The phenotype suggests that PMA treatment of HEL/EDG6 can produce cell populations resembling terminally differentiated megakaryocytes. Interestingly, an up-regulation of a key enzyme regulating S1P production, sphingosine kinase-1, by PMA is reported in HEL cells [Buehrer B.M., E. S. Bardes, R. M. Bell, (1996)]. The observed prominent change of phenotype, thus can potentially be attributed to a rapid accumulation of S1P after treatment of PMA. As PMA is a pleiotropic substance, it is not easy to

elucidate direct roles of sphingosine kinase in the phenomena. Nevertheless, our comparison of PMA-induced cell morphologies among HEL/EDG6, HEL/CV, and HEL cells stably transfected with an expression vector encoding S1P<sub>1</sub> (HEL/S1P<sub>1</sub>) showed clear differences, implying that either the cells were at different differentiation stages before the PMA treatment or that S1P signals and PMA together determine the cell shapes.

These data strongly suggest a crucial role for EDG6 in thrombopoiesis.

#### **Example 17: Effect of Rho family of GTPases on morphogenesis of cytosolic extensions**

It is particularly interesting that, unlike HEL/CV, HEL/EDG6 displays cytoplasmic processes similar to megakaryocytes upon PMA treatment. To obtain an insight into potential mechanisms, we treated HEL/EDG6 and HEL/CV with a variety of cytoskeletal modulators in the presence of PMA. Among those tested, Y27632, a Rho-kinase inhibitor [M. Uehata *et al.*, (1997)], induced cytosolic extensions in HEL/CV, while it did not induce any further effect on HEL/EDG6 (data not shown). To test if suppression of the Rho-kinase pathway is responsible for the formation of cytosolic extensions, the cells were treated with C3 exoenzyme, a Rho inhibitor, before PMA treatment. C3 exoenzyme treatment of HEL/CV by itself induced a morphological phenotype similar to HEL/EDG6 (Fig. 3B). HEL/EDG6 also appeared not to be affected by C3 exoenzyme treatment. These data hinted that the Rho pathway is suppressed or overridden in HEL/EDG6 facilitating the process formation that is a prerequisite for platelet release. Alternatively, activation of other Rho family GTPases might cause the process formation, since reciprocal regulation between Rho and Rac/Cdc42 is observed in some cell types [E. E. Sandera, *et al.*, (1999)].

Activation of Rho, Rac, and Cdc42, were investigated in HEL/CV and HEL/EDG6 after serum starvation and subsequent stimulation with S1P. We observed up-regulation of GTP-Rac by S1P in both HEL/EDG6 and HEL/CV cells. GTP-Cdc42

was increased and GTP-Rho was decreased in HEL/EDG6 cells treated with S1P but not in HEL/CV cells (data not shown). The observations suggest that S1P up-regulates Cdc42 and down-regulates Rho signaling through EDG6. The observed reciprocal regulatory patterns matched well with those in HEL/CV and HEL/EDG6 cells cultured in the medium supplemented with 10 % FBS, which contains S1P. In the presence of serum, the GTP-bound form of Rac and Rho were abundant in HEL/CV, in contrast, the GTP-bound form of Rac and Cdc42 were rich in HEL/EDG6 (data not shown). The observation that HEL/EDG6 possesses an ability to resemble megakaryocytes in culture medium containing FBS reinforces the results demonstrating that up-regulation of Cdc42 and down-regulation of Rho signaling by S1P through EDG6 are important for the phenotype. It is intriguing to note that the effector molecule downstream of Cdc42 is WASP, the protein mutated in Wiskott-Aldrich syndrome patients, and that one of the phenotypes of the deficiency of WAS protein is severe thrombocytopenia [J. M. Derry, H. D. Ochs, U. Francke, (1994)]. WASP, indeed, was detected in HEL cell lysates (data not shown). Our experimental results thus suggest a mechanism by which S1P regulates the formation of megakaryocyte processes and platelet release, and why thrombocytopenia may occur in the patients with Wiskott-Aldrich syndrome (Fig. 8).

The reciprocal activation of Rac/Cdc42 and Rho is implicated in the guidance of axonal growth cone in the neurite outgrowth. It is fascinating to speculate, in an analogy to the axon extension, that in the blood sinus in bone marrow, megakaryocyte processes are guided by S1P receptors toward plasma, which contains their cognate ligand, through holes in the blood vessels. In this way, fragmented cytosolic extensions, platelets, may be released into the circulation.

Examples 15 to 17 clearly demonstrate, that an agonist of EDG6 can be used to treat conditions where platelet counts are low (thrombocytopenia) including but not limited to drug-induced thrombocytopenia (e.g. following cancer chemotherapy), radiotherapy-induced thrombocytopenia, thrombocytopenia following bone marrow

transplantation, immune thrombocytopenia (due to increased degradation of platelets) and congenital thrombocytopenia.

**Table 2:** Summary of Primers and PCR Conditions Used in Examples 15-17

5

Gene	Primer sequence	Annealing (°C)	Cycles
S1P <sub>1</sub>	sense: 5'-GTGGGCTGCAAGGTGAAGACCTGT-3' SEQ ID NO:6 antisense: 5'-TTTCTGGGGGTGGGAGGAATTGTC-3' SEQ ID NO:7	60	35-40
S1P <sub>2</sub>	sense: 5'-GTCATCCTCTGTGTGCGCCATTGTG-3' SEQ ID NO:8 antisense: 5'-AGGCTGAAGACAGAGGCCGAGAGC-3' SEQ ID NO:9	60	35-40
S1P <sub>3</sub>	sense: 5'-GCCCCATCCTCTTCAAGGCTCAGT-3' SEQ ID NO:10 antisense: 5'-GTGGGGCAGGTCTTCCTTGACCTT-3' SEQ ID NO:11	60	35-40
EDG6	sense: 5'-TCCAGCCTTCTGCCCTCTACTCC-3' SEQ ID NO:12 antisense: 5'-CAGGAAGGCCAGCAGGATCATCAG-3' SEQ ID NO:13	60	35-40
S1P <sub>5</sub>	sense: 5'-AGGACTTCGCTTTTGCTCTG-3' SEQ ID NO:14 antisense: 5'-TCTAGAATCCACGGGGTCTG-3' SEQ ID NO:15	60	35-40
GATA-1	sense: 5'-CACCTGGTGTAGCTTGTAGT-3' SEQ ID NO:16 antisense: 5'-CCCAAGCTTCGTGGAAGTCT-3' SEQ ID NO:17	58	31
GATA-2	sense: 5'-TGTTGTGCAAATTGTCAGACG-3' SEQ ID NO:18 antisense: 5'-CATAGGTGCCATGTGTCCAGC-3' SEQ ID NO:19	57	42
Fli-1	sense: 5'-CGCCACCACCCTCTACAACACGGAA-3' SEQ ID NO:20 antisense: 5'-CGGGCCCAGGATCTGATACGGATCT-3' SEQ ID NO:21	58	28
NF-E2	sense: 5'-ATCATGTCCATCACCGAGCTGC-3' SEQ ID NO:22 antisense: 5'-TGGGTCTTCTTGGGGCTTAGGT-3' SEQ ID NO:23	58	31
FOG-2	sense: 5'-GCTAAGATGTCTGAAGTGGT-3' SEQ ID NO:24 antisense: 5'-GGACCATGTATGTTTCGTGC-3' SEQ ID NO:25	58	34

Gene	Primer sequence	Annealing (°C)	Cycles
cMPL	sense: 5'-TGGAGATGCAGTGGCACTTG-3' SEQ ID NO: 26 antisense: 5'-AGAACTGTGGGGTCTGTAGT-3' SEQ ID NO: 27	58	35
RGS18	sense: 5'-TGA CTGAGAATAAGATCCACATTTGAA-3' SEQ ID NO: 28 antisense: 5'-CATGTTTCTGTGACCAACAGAAGTACT-3' SEQ ID NO: 29	58	34
2- micro- globulin	sense: 5'-AGATT CAGGTTTACTCACGTCA-3' SEQ ID NO: 30 antisense: 5'-TATCTTGGGCTGTGACAAAGT-3' SEQ ID NO: 31	60	40
G3PDH	sense: 5'-ACCACAGTCCATGCCATCAC-3' SEQ ID NO: 32 antisense: 5'-TCCACCACCCTGTTGCTGTA-3' SEQ ID NO: 33	58	28

### Materials and Methods

**Colony formation assay and preparation of CD41<sup>+</sup> cells:** Cord blood CD34<sup>+</sup> cells and bone marrow CD34<sup>+</sup> cells (Bio Whittaker, MD) were cultured in serum-free Iscove's modified Dulbecco's medium for 2 days. The cells (2500 / well) were seeded on a collagen-based semisolid culture substrate in the defined serum-free medium (Iscove's modified Dulbecco's medium containing 50 ng / ml of rhTPO, 10 ng / ml of IL-6, and 10 ng / ml of rhIL-3) provided with Megacult-C<sup>TM</sup> for human megakaryocytic progenitor assay (Stem Cell Technologies, Canada), in the presence or absence of 10  $\mu$ M S1P. The chambers were incubated at 37°C in a 5 % CO<sub>2</sub> atmosphere for 12 days then megakaryocyte colonies (CFU-MK) were stained for CD41 and scored following the manufacturer's procedure. For isolation of CD41<sup>+</sup> cells, cord blood CD34<sup>+</sup> cells were cultured in the defined serum-free medium (described above) for 12 days. CD41<sup>+</sup> cells were isolated by MiniMACS system (Mitenyi Biotec Inc., Germany) using an anti-human CD41 antibody (DAKO, Denmark) and Goat anti-mouse IgG Micro Beads (Mitenyi Biotec Inc., Germany).

**Preparation of HEL cell transfectants:** HEL 92,1,7 (HEL, ATCC# TIB-180) cells were maintained in RPMI1640 containing 10 % FBS (JRH Biosciences, KS), 10 mM Hepes. HEL cells (5 million) were transfected with 20  $\mu$ g of an expression vector

encoding human S1P<sub>4</sub> (pcDNA3.1-Igγ-HA-hS1P<sub>4</sub>), S1P<sub>1</sub> (pcDNA3.1-Igγ-Flag-hS1P<sub>1</sub>) or a control vector (pcDNA3.1) by electroporation (250 V at 960 μF). The cells were grown in culture medium containing 0.5 mg / ml of G418 (Invitrogen Corp., CA). Stable clones expressing S1P<sub>4</sub> were obtained by limiting dilution  
5 followed by the flow cytometric analysis with anti-HA antibody.

**RT-PCR:** Total RNA was isolated from cells and platelets using TRIzol Reagent (Invitrogen Corp., CA) and reverse-transcribed using SuperScript II Rnase H<sup>-</sup> Reverse Transcriptase (Invitrogen Corp., CA) with random primers. For CD34<sup>+</sup>  
10 progenitor cells, cDNA was synthesized using the Cells-to-cDNA kit (Ambion Inc., TX). PCR reactions were performed with HotStarTaq Master Mix Kit (Qiagen, Germany). The cycle number of PCR that is not saturated was empirically determined for each target. Primers and PCR conditions used in this study are summarized in Supplemental Table. PCR products were separated on agarose gels  
15 and visualized by ethidium bromide staining.

**Immunocytochemistry and fluorescence microscopy:** Cells were cultured on glass slides, fixed with 3.7 % formaldehyde, and permeabilized with 0.5 % TritonX-100. Fixed samples were blocked with 5 % human serum, incubated with an anti-HA  
20 antibody conjugated with fluorescein isothiocyanate (Santa Cruz, CA) or Hoechst 33342 (Calbiochem, CA), washed, and mounted. Slides were examined under incident-light fluorescence microscope (Olympus IX-70, Japan), and photographs were taken with a SPOT digital camera system (Diagnostic Instruments, inc., MI).

**Morphogenesis assay:** Ten million cells were plated on a 24-well plate with or without 30 μM of the Rho-kinase inhibitor Y27632 (Calbiochem, CA). PMA (10 nM final) was added to the culture 30 minutes after plating. Cells were cultured for 72 hours and photographed. For studies using C3 exoenzyme, 2 x 10<sup>5</sup> cells in 0.5 ml culture medium were plated on a 24-well plate with or without 3 μg / ml of C3  
25 exoenzyme (Upstate, NY), and cultured overnight. Fresh culture medium containing  
30 PMA and C3 exoenzyme was added to each well to give final PMA and C3

exoenzyme concentrations at 10 nM and 3 µg / ml, respectively. Cells were cultured for 72 hours and photographed.

5 **Flow cytometry:** Cultured cells were incubated for 30 minutes on ice with anti-human CD41 monoclonal antibody (Stem Cell Technologies, Canada) or mouse IgG (Santa Cruz, CA) in PBS containing 0.5% BSA and 0.05% sodium azide. After washing, the cells were incubated for 30 minutes on ice with FITC-labeled anti-mouse IgG (Santa Cruz, CA) in PBS containing 0.5% BSA and 0.05% sodium azide. For the platelet-like particles and platelets, the same staining procedures were carried  
10 out at room temperature. Samples were analyzed on a flow cytometer (Becton Dickinson, NJ).

**Isolation of platelets and platelet-like particles:** Blood from healthy donors was collected into centrifuge tubes containing 20 mM sodium dihydrogenphosphate dehydrate, 17 mM citric acid, 90 mM sodium citrate, and 13 mM Dextrose.  
15 HEL/S1P<sub>4</sub> cells were cultured until cells released cytoplasmic particles (typically 10 - 18 days). Preparations were centrifuged at 200g for 15 minutes. Supernatants obtained were centrifuged at 1600g for 15 minutes. Sediments containing platelets or platelet-like particles were used in the experiments.

20 **PF4 release:** Platelet-like particles were suspended in Dulbecco's modified Eagle medium (DMEM) and stimulated with 100 nM PMA or 50 µM ADP for 10 minutes. For thrombin stimulation, samples were incubated with 0.5 units / ml thrombin for 2 minutes at 37°C. The samples were also lysed with 0.2 % Triton X-100 as the control  
25 for the total PF4 content. After stimulation, an equal volume of DMEM containing 1 % BSA was added, and supernatants were collected by centrifugation at 12000g for 10min. Platelet factor 4 in supernatants was measured with ZymutestPF4 enzyme-linked immunosorbent assay (Hyphen BioMed, France).

30 **Rho, Rac and cdc42 assays:** Cells (5 x 10<sup>6</sup> for Cdc42 and Rac, 1 x 10<sup>7</sup> for Rho) were harvested and lysed with 50 mM Tris (pH 7.5), 100 mM NaCl, 1% Triton X-100,

5 mM MgCl<sub>2</sub> containing protease inhibitors (Complete™, EDTA-free, Roche Diagnostics, Germany). Cell lysates were clarified by centrifugation at 15000g at 4°C for 5 minutes, and incubated with PAK-1 PBD agarose, Rhotekin RBD agarose (Upstate, NY) and GST-WASP GBD beads (kindly provided by Tatsuo Kinashi, Kyoto University) at 4°C for 45 minutes with constant rotation. The bound, active forms of Rac or Rho or cdc42 proteins were detected by Western Blot analysis using anti-Rac, anti-Rho and anti-cdc42 antibodies (Upstate, NY). The amounts of Rho, Rac, cdc42, and WASP in 20 µg of whole cell lysates were also analyzed by Western Blot. After incubating with HRP-conjugated secondary antibodies, the blots were developed with ECL-Plus (Amersham Biosciences, UK). For examination of Rho, Rac and cdc42 responses to S1P treatment, cells were maintained in RPMI1640 containing 0.1% fatty-acid free BSA (Sigma) overnight. Cells were harvested and suspended in PBS, and stimulated with 1 µM S1P at 37°C for 1 minute before cell lysis. Rho, Rac, and cdc42 in 20 µg of the whole cell lysates were also analyzed by Western blot for examination of protein expression. WASP in 20 µg of the whole cell lysates was detected using an anti-WASP antibody (Sigma, MO).

### References

- 20 U.S. 4,522,811
- U.S. 5,283,317
- U.S. 5,565,332
- U.S. 5,585,476
- U.S. 5,856,443
- 25 U.S. 5,912,144
- U.S. 6,130,067
- U.S. 6,323,333
- U.S. 6,485,922
- WO 84/03564
- 30 WO 92/01810
- WO 93/03151



- WO 94/13804  
 WO 00/14233  
 WO 01/04297  
 WO 02/06446
- 5 Altschul SF; Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ;  
 Nucleic Acids Res 1997 Sep 1; 25(17): 3389-402  
 Appa Rao et al., 1997, Protein Expr Purif Nov, 11(2): 201-8  
 Barnes, 2000, Chest, 117:10S14S  
 Botstein et al., 1980, Am J Hum Genet. 32: 314-31
- 10 Buehrer et al., *Biochem. Biophys. Acta* 1303, 233 (1996).  
 Colbere-Garapin et al., 1981, *J. Mol. Biol.* 150, 1-14  
 Derry, et al., *Cell* 78, 635, (1994).  
 Engelhard et al., 1994, *Proc. Nat. Acad. Sci.* 91, 3224-3227.  
 Gergen and Weiss, 1992, Am Rev Respir Dis 146:823-824
- 15 Gibson et al., 1996, Genome Research 6: 995-1001  
 Graler et al., Cytogenet. Cell. Genet. 65: 140, 1994  
 Haseloff et al., 1988, *Nature* 334, 585-591  
 Heid et al., 1996, Genome Research 6: 986-994  
 Holland et al., 1991, PNAS 88: 7276-7280
- 20 Iwabuchi et al., 1993, *Oncogene* 8, 1693-1696  
 Jedlicka et al., Genomics 53: 164-169, 1998  
 Jeffreys et al., 1985, Nature 316: 76-9  
 Johnson et al., 1989, *Endoc. Rev.* 10, 317-331  
 Kellogg et al., 1990, Anal. Biochem. 189:202-208
- 25 Lam, 1997, Anticancer Drug Res. 12(3):145-67  
 Lefkowitz, 1991, *Nature* 351, 353-354  
 Livak et al., 1995, PCR Methods and Applications 357-362  
 Logan, Shenk, 1984, *Proc. Natl. Acad. Sci.* 81, 3655-3659  
 Lowy et al., 1980, *Cell* 22, 817-23
- 30 Maddox et al., 1983, *J. Exp. Med.* 158, 1211-1216  
 McConnell et al., 1992, *Science* 257, 1906-1912

- Nicholls *et al.*, 1993, *J. Immunol. Meth.* 165, 81-91
- Piatak *et al.*, 1993, *BioTechniques* 14:70-81
- Piatak *et al.*, 1993, *Science* 259:1749-1754
- Porath *et al.*, 1992, *Prot. Exp. Purif.* 3, 263-281
- 5 Roberge *et al.*, 1995, *Science* 269, 202-204
- Sandera, *et al.*, *J. Cell Biol.* 147, 1009 (1999).
- Sjolander, Urbaniczky, 1991, *Anal. Chem.* 63, 2338-2345
- Szabo *et al.*, 1995, *Curr. Opin. Struct. Biol.* 5, 699-705
- Thomas, 1980, *Proc. Nat. Acad. Sci.*, 77:5201-5205
- 10 Uehata *et al.*, *Nature* 389, 990 (1997)
- Uhlmann *et al.*, 1987, *Tetrahedron. Lett.* 215, 3539-3542
- Weber *et al.*, 1990, *Genomics* 7: 524-30
- Wigler *et al.*, 1977, *Cell* 11, 223-32
- Wigler *et al.*, 1980, *Proc. Natl. Acad. Sci.* 77, 3567-70
- 15 Yamazaki Y *et al.*, *Biochem Biophys Res Commun* 2000 Feb 16;268(2):583-9

Claims

1. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal comprising the steps of
  - i) contacting a test compound with a EDG6 polypeptide,
  - ii) detect binding of said test compound to said EDG6 polypeptide.
2. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal comprising the steps of
  - i) determining the activity of a EDG6 polypeptide at a certain concentration of a test compound or in the absence of said test compound,
  - ii) determining the activity of said polypeptide at a different concentration of said test compound.
3. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological

disorders, thrombocytopenia and myeloma in a mammal comprising the steps of

5           i)       determining the activity of a EDG6 polypeptide at a certain concentration of a test compound,

          ii)       determining the activity of a EDG6 polypeptide at the presence of a compound known to be a regulator of a EDG6 polypeptide.

10       4.       The method of any of claims 1 to 3, wherein the step of contacting is in or at the surface of a cell.

5.       The method of any of claims 1 to 3, wherein the cell is in vitro.

15       6.       The method of any of claims 1 to 3, wherein the step of contacting is in a cell-free system.

7.       The method of any of claims 1 to 3, wherein the polypeptide is coupled to a detectable label.

20       8.       The method of any of claims 1 to 3, wherein the compound is coupled to a detectable label.

25       9.       The method of any of claims 1 to 3, wherein the test compound displaces a ligand which is first bound to the polypeptide.

10.       The method of any of claims 1 to 3, wherein the polypeptide is attached to a solid support.

30       11.       The method of any of claims 1 to 3, wherein the compound is attached to a solid support.

12. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal comprising the steps of
- 5
- i) contacting a test compound with a EDG6 polynucleotide,
- 10
- ii) detect binding of said test compound to said EDG6 polynucleotide.
13. The method of claim 12 wherein the nucleic acid molecule is RNA.
14. The method of claim 12 wherein the contacting step is in or at the surface of a cell.
- 15
15. The method of claim 12 wherein the contacting step is in a cell-free system.
16. The method of claim 12 wherein polynucleotide is coupled to a detectable label.
- 20
17. The method of claim 12 wherein the test compound is coupled to a detectable label.
- 25
18. A method of diagnosing a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal comprising the steps of
- 30

- i) determining the amount of a EDG6 polynucleotide in a sample taken from said mammal,
- ii) determining the amount of EDG6 polynucleotide in healthy and/or diseased mammals.

5

19. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal comprising a therapeutic agent which binds to a EDG6 polypeptide.

10

20. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular disorders; gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal comprising a therapeutic agent which regulates the activity of a EDG6 polypeptide.

15

20

21. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal comprising a therapeutic agent which regulates the activity of a EDG6 polypeptide, wherein said therapeutic agent is

25

- i) a small molecule,
- ii) an RNA molecule,
- iii) an antisense oligonucleotide,
- iv) a polypeptide,

30

- v) an antibody, or
- vi) a ribozyme.

- 5           22. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal comprising a EDG6 polynucleotide.
- 10          23. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal comprising a EDG6 polypeptide.
- 15
- 20          24. Use of regulators of a EDG6 for the preparation of a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal.
- 25          25. Method for the preparation of a pharmaceutical composition useful for the treatment of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal comprising the steps of
- 30           i) identifying a regulator of EDG6,

ii) determining whether said regulator ameliorates the symptoms of a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma in a mammal; and

iii) combining of said regulator with an acceptable pharmaceutical carrier.

10 26. Use of a regulator of EDG6 for the regulation of EDG6 activity in a mammal having a disease comprised in a group of diseases consisting of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma.



**Diagnostics and Therapeutics for Diseases Associated with Endothelial Differentiation, Sphingolipid G-Protein-Coupled Receptor 6 (EDG6)**

**Abstract of Disclosure**

The invention provides a human EDG6 which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma. The invention also features compounds which bind to and/or activate or inhibit the activity of EDG6 as well as pharmaceutical compositions comprising such compounds.

EPO - Munich  
67  
28. März 2003Fig. 1

SEQ ID NO: 1

GAGTCAGCCCCCGGGGAGGCCATGAACGCCACGGGGACCCCGGTGGC  
CCCCGAGTCCTGCCAACAGCTGGCGGCCGGCGGGCACAGCCGGCTCAT  
TGTTCTGCACTACAACCACTCGGGCCGGCTGGCCGGGCGCGGGGGGCC  
GGAGGATGGCGGCCTGGGGGCCCTGCGGGGGCTGTCGGTGGCCGCCAG  
CTGCCTGGTGGTGCTGGAGAACTTGCTGGTGGTGGCGGCCATCACCAG  
CCACATGCGGTGCGGACGCTGGGTCTACTATTGCCTGGTGAACATCAC  
GCTGAGTGACCTGCTCACGGGCGCGGCCTACCTGGCCAACGTGCTGCT  
GTCGGGGGCCCCGCACCTTCCGTCTGGCGCCCGCCCAGTGGTTCCTACG  
GGAGGGCCTGCTCTTCACCGCCCTGGCCGCCTCCACCTTCAGCCTGCT  
CTTCACTGCAGGGGAGCGCTTTGCCACCATGGTGCGGCCGGTGGCCGA  
GAGCGGGGCCACCAAGACCAGCCGCGTCTACGGCTTCATCGGCCTCTG  
CTGGCTGCTGGCCGCGCTGCTGGGGATGCTGCCTTTGCTGGGCTGGAA  
CTGCCTGTGCGCCTTTGACCGCTGCTCCAGCCTTCTGCCCCTCTACTC  
CAAGCGCTACATCCTCTTCTGCCTGGTGATCTTCGCCGGCGTCCTGGC  
CACCATCATGGGCCTCTATGGGGCCATCTTCCGCCTGGTGCAGGCCAG  
CGGGCAGAAGGCCCCACGCCAGCGGCCCGCCGCAAGGCCCGCCGCCT  
GCTGAAGACGGTGCTGATGATCCTGCTGGCCTTCCTGGTGTGCTGGGG  
CCCACTCTTCGGGCTGCTGCTGGCCGACGTCTTTGGCTCCAACCTCTG  
GGCCAGGAGTACCTGCGGGGCATGGACTGGATCCTGGCCCTGGCCGT  
CCTCAACTCGGCGGTCAACCCCATCATCTACTCCTTCCGCAGCAGGGA  
GGTGTGCAGAGCCGTGCTCAGCTTCCTCTGCTGCGGGTGTCTCCGGCT  
GGGCATGCGAGGGCCCGGGGACTGCCTGGCCCCGGGCCGTGAGGCTCA  
CTCCGGAGCTTCCACCACCGACAGCTCTCTGAGGCCAAGGGACAGCTT  
TCGCGGCTCCCGCTCGCTCAGCTTTCGGATGCGGGAGCCCCTGTCCAG  
CATCTCCAGCGTGCGGAGCATCTGAAGTTGAGTCTTGCGTGTGGATG  
GTGCAGCCACCGGGTGCGTGCCAGGCAGGCCCTCCTGGGGTACAGGAA  
GCTGTGTGCACGCAGCCTCGCCTGTATGGGGAGCAGGGAACGGGACAG

Fig. 1 (continued)

GCCCCCATGGTCTTCCCGGTGGCCTCTCGGGGCTTCTGACGCCAAATG  
GGCTTCCCATGGTCACCCTGGACAAGGAGGTAACCACCCACCTCCCC  
GTAGGAGCAGAGAGCACCCTGGTGTGGGGGCGAGTGGTTCCCACAAC  
CCCGCTTCTGTGTGATTCTGGGGAAGTCCCGGCCCTCTCTGGGCCTC  
AGTAGGGCTCCCAGGCTGCAAGGGGTGGACTGTGGGATGCATGCCCTG  
GCAACATTGAAGTTCGATCATGGTAAAAAA

Fig. 2

SEQ ID NO: 2

MNATGTPVAPESCQQLAAGGHSRLIVLHYNHSGRLAGRGGPEDGGLGA  
LRGLSVAASCLVVLENLLVLAAITSHMRSRRWVYYCLVNITLSDLLTG  
AAYLANVLLSGARTFRLAPAQWFLREGLLFTALAASTFSLLFTAGERF  
ATMVRPVAESGATKTSRVYGFIGLCWLLAALLGMLPLLGNCLCAFDR  
CSSLLPLYSKRYILFCLVIFAGVLATIMGLYGAI FRLVQASGQKAPRP  
AARRKARRLLKTVLMILLAFVLCWGPLFGLLLADVFGSNLWAQEYLRG  
MDWILALAVLNSAVNP I IYSFRSREVCRAVLSFLCCGCLRLGMRGPGD  
CLARAVEAHSGASTTDSSLRPRDSFRGSRSLSFRMREPLSSISSVRSI

Fig. 3

SEQ ID NO: 3

5' - GTCTTTGGCTCCAACCTCTG -3'

Fig. 4

SEQ ID NO: 4

5' - GGCCAGGATCCAGTCCAT -3'


Fig. 5

SEQ ID NO: 5


5' - CCCAGGAGTACCTGCGGGGC -3'

**Fig. 6 A**

**Bone Marrow CD34<sup>+</sup>**



**Cord Blood CD34<sup>+</sup>**






**Fig. 6 B**

Fig. 7



**Fig. 8**



EPO - Munich  
67  
28. März 2003

## SEQUENCE LISTING

&lt;110&gt; Bayer AG, BHC

&lt;120&gt; Diagnostics and Therapeutics for Diseases Associated with Endothelial Differentiation, Sphingolipid G-Protein-Coupled Receptor 6 (EDG6)

&lt;130&gt; Le A 36 643

&lt;160&gt; 33

&lt;170&gt; PatentIn version 3.1

&lt;210&gt; 1

&lt;211&gt; 1566

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

```

gagtcagccc ccgggggagg ccatgaacgc cacggggacc cgggtggccc ccgagtcctg      60
ccaacagctg gcggccggcg ggcacagccg gctcattgtt ctgcactaca accactcggg      120
ccggctggcc gggcgcgggg ggccggaggga tggcggcctg gggggcctgc gggggctgtc      180
ggtggccgcc agctgcctgg tgggtgctgga gaacttgctg gtgctggcgg ccatcaccag      240
ccacatgcgg tcgcgacgct ggggtctacta ttgcctgggtg aacatcacgc tgagtgaacct      300
gctcacgggc gcggcctacc tggccaacgt gctgctgtcg ggggcccga ccttcctgtc      360
ggcgcccgcc cagtgggtcc tacgggaggg cctgctcttc accgccctgg ccgcctccac      420
cttcagcctg ctcttcaact caggggagcg ctttgccacc atggtgcggc cgggtggccga      480
gagcggggcc accaagacca gccgcgtcta cggcttcacg ggcctctgct ggctgctggc      540
cgcgctgctg gggatgctgc ctttgctggg ctggaactgc ctgtgcgctt ttgaccgtg      600
ctccagcctt ctgcccctct actccaagcg ctacatcctc ttctgcctgg tgatcttcgc      660
cggcgtcctg gccaccatca tgggcctcta tggggccacc ttccgcctgg tgcaggccag      720
cgggcagaag gccccacgcc cagcgcccg ccgcaaggcc cgcgcctgc tgaagacggg      780
gctgatgatc ctgctggcct tcctgggtgtg ctggggccca ctcttcgggc tgctgctggc      840
cgacgtcttt ggtccaacc tctgggcccga ggagtacctg cggggcatgg actggatcct      900
ggcctggcc gtcctcaact cggcggtcaa ccccatcatc tactccttcc gcagcaggga      960
ggtgtgcaga gccgtgctca gcttctctg ggctcactcc ggagcttcca ccaccgacag      1020
gcccggggac tgcctggccc gggcgctcga ggctcactcc ggagcttcca ccaccgacag      1080
ctctctgagg ccaagggaca gctttcgcg ctcccgctcg ctccagcttc ggatgcggga      1140
gccctgtccc agcatctcca gcgtgcggag catctgaagt tgcagtcttg cgtgtggatg      1200
gtgcagccac cgggtgcgtg ccaggcaggc cctcctgggg tacaggaagc tgtgtgcacg      1260
cagcctcgcc tgtatgggga gcagggaacg ggacaggccc ccatggtott cccggtggcc      1320
tctcggggct tctgacgcca aatgggcttc ccatggtcac cctggacaag gaggttaacca      1380
ccccacctcc ccgtaggagc agagagcacc ctggtgtggg ggcgagtggg tccccacaac      1440
cccgttctg tgtgattctg gggaagtccc ggcctctc tcgggcctcag tagggctccc      1500
aggctgcaag ggttggaactg tgggatgcat gccctggcaa cattgaagtt cgatcatggt      1560
aaaaaa

```

&lt;210&gt; 2

&lt;211&gt; 384

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```

Met Asn Ala Thr Gly Thr Pro Val Ala Pro Glu Ser Cys Gln Gln Leu
1      5      10      15
Ala Ala Gly Gly His Ser Arg Leu Ile Val Leu His Tyr Asn His Ser
20     25     30
Gly Arg Leu Ala Gly Arg Gly Gly Pro Glu Asp Gly Gly Leu Gly Ala
35     40     45
Leu Arg Gly Leu Ser Val Ala Ala Ser Cys Leu Val Val Leu Glu Asn
50     55     60
Leu Leu Val Leu Ala Ala Ile Thr Ser His Met Arg Ser Arg Arg Trp
65     70     75     80
Val Tyr Tyr Cys Leu Val Asn Ile Thr Leu Ser Asp Leu Leu Thr Gly
85     90     95
Ala Ala Tyr Leu Ala Asn Val Leu Leu Ser Gly Ala Arg Thr Phe Arg
100    105    110

```

- 2 -

Leu Ala Pro Ala Gln Trp Phe Leu Arg Glu Gly Leu Leu Phe Thr Ala  
 115 120 125  
 Leu Ala Ala Ser Thr Phe Ser Leu Leu Phe Thr Ala Gly Glu Arg Phe  
 130 135 140  
 Ala Thr Met Val Arg Pro Val Ala Glu Ser Gly Ala Thr Lys Thr Ser  
 145 150 155 160  
 Arg Val Tyr Gly Phe Ile Gly Leu Cys Trp Leu Leu Ala Ala Leu Leu  
 165 170 175  
 Gly Met Leu Pro Leu Leu Gly Trp Asn Cys Leu Cys Ala Phe Asp Arg  
 180 185 190  
 Cys Ser Ser Leu Leu Pro Leu Tyr Ser Lys Arg Tyr Ile Leu Phe Cys  
 195 200 205  
 Leu Val Ile Phe Ala Gly Val Leu Ala Thr Ile Met Gly Leu Tyr Gly  
 210 215 220  
 Ala Ile Phe Arg Leu Val Gln Ala Ser Gly Gln Lys Ala Pro Arg Pro  
 225 230 235 240  
 Ala Ala Arg Arg Lys Ala Arg Arg Leu Leu Lys Thr Val Leu Met Ile  
 245 250 255  
 Leu Leu Ala Phe Leu Val Cys Trp Gly Pro Leu Phe Gly Leu Leu Leu  
 260 265 270  
 Ala Asp Val Phe Gly Ser Asn Leu Trp Ala Gln Glu Tyr Leu Arg Gly  
 275 280 285  
 Met Asp Trp Ile Leu Ala Leu Ala Val Leu Asn Ser Ala Val Asn Pro  
 290 295 300  
 Ile Ile Tyr Ser Phe Arg Ser Arg Glu Val Cys Arg Ala Val Leu Ser  
 305 310 315 320  
 Phe Leu Cys Cys Gly Cys Leu Arg Leu Gly Met Arg Gly Pro Gly Asp  
 325 330 335  
 Cys Leu Ala Arg Ala Val Glu Ala His Ser Gly Ala Ser Thr Thr Asp  
 340 345 350  
 Ser Ser Leu Arg Pro Arg Asp Ser Phe Arg Gly Ser Arg Ser Leu Ser  
 355 360 365  
 Phe Arg Met Arg Glu Pro Leu Ser Ser Ile Ser Ser Val Arg Ser Ile  
 370 375 380

<210> 3  
 <211> 20  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> forward primer

<400> 3  
 gtcttttggt ccaacctctg

20

<210> 4  
 <211> 18  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> reverse primer

<400> 4  
 ggccaggatc cagtccat

18

<210> 5  
 <211> 20  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> probe

<400> 5  
 cccaggagta cctgcggggc

20

<210> 6  
 <211> 24  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> S1P1 sense primer

<400> 6  
 gtgggctgca aggtgaagac ctgt

24

<210> 7  
 <211> 24  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> S1P1 antisense primer

<400> 7  
 tttctggggg tgggaggaat tgtc

24

<210> 8  
 <211> 24  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> S1P2 sense primer

<400> 8  
 gtcacacctct gttgcgccat tgtg

24

<210> 9  
 <211> 24  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> S1P2 antisense primer

<400> 9  
 aggctgaaga cagaggccga gagc

24

<210> 10  
 <211> 24  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> S1P3 sense primer

<400> 10  
 gccccatcct cttcaaggct cagt

24

<210> 11  
 <211> 24  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> S1P3 antisense primer

<400> 11  
 gtggggcagg tcttccttga cctt

24

<210> 12  
 <211> 24

<212> DNA  
<213> artificial sequence

<220>  
<223> S1P4 sense primer

<400> 12  
tccagccttc tgcccctcta ctcc

24

<210> 13  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>  
<223> S1P4 antisense primer

<400> 13  
caggaaggcc agcaggatca tcag

24

<210> 14  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>  
<223> S1P5 sense primer

<400> 14  
aggacttcgc ttttgctctg

20

<210> 15  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>  
<223> S1P5 antisense primer

<400> 15  
tctagaatcc acggggtctg

20

<210> 16  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>  
<223> GATA-1 sense primer

<400> 16  
cacctgggtg agctttagt

20

<210> 17  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>  
<223> GATA-1 antisense primer

<400> 17  
cccaagcttc gtggaactct

20

<210> 18  
<211> 21  
<212> DNA

<213> artificial sequence

<220>

<223> GATA-2 sense primer

<400> 18  
tggtgtgcaa attgtcagac g 21

<210> 19

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> GATA-2 antisense primer

<400> 19  
cataggtgcc atgtgtccag c 21

<210> 20

<211> 25

<212> DNA

<213> artificial sequence

<220>

<223> Fli-1 sense primer

<400> 20  
cgccaccacc ctctacaaca cggaa 25

<210> 21

<211> 25

<212> DNA

<213> artificial sequence

<220>

<223> Fli-1 antisense primer

<400> 21  
cgggcccagg atctgatagc gatct 25

<210> 22

<211> 22

<212> DNA

<213> artificial sequence

<220>

<223> NF-E2 sense primer

<400> 22  
atcatgtcca tcaccgagct gc 22

<210> 23

<211> 22

<212> DNA

<213> artificial sequence

<220>

<223> NF-E2 antisense primer

<400> 23  
tgggtcttct tggggcttag gt 22

<210> 24

<211> 20

<212> DNA

<213> artificial sequence

```

<220>
<223> FOG-2 sense primer

<400> 24                                20
gctaagatgt ctgaactggt

<210> 25
<211> 20
<212> DNA
<213> artificial sequence

<220>
<223> FOG-2 antisense primer

<400> 25                                20
ggaccatgta tgtttcgtgc

<210> 26
<211> 20
<212> DNA
<213> artificial sequence

<220>
<223> cMPL sense primer

<400> 26                                20
tggagatgca gtggcacttg

<210> 27
<211> 20
<212> DNA
<213> artificial sequence

<220>
<223> cMPL antisense primer

<400> 27                                20
agaactgtgg ggtctgtagt

<210> 28
<211> 27
<212> DNA
<213> artificial sequence

<220>
<223> RGS18 sense primer

<400> 28                                27
tgactgagaa taagatccac atttgaa

<210> 29
<211> 27
<212> DNA
<213> artificial sequence

<220>
<223> RGS18 antisense primer

<400> 29                                27
catgtttctg tgaccaacag aagtact

<210> 30
<211> 22
<212> DNA
<213> artificial sequence

<220>
<223> beta-2 microglobulin sense primer

```

<400> 30  
agattcaggt ttactcacgt ca 22

<210> 31  
<211> 21  
<212> DNA  
<213> artificial sequence

<220>  
<223> beta-2 microglobulin antisense primer

<400> 31  
tatcttgggc tgtgacaaag t 21

<210> 32  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>  
<223> G3PDH sense primer

<400> 32  
accacagtcc atgccatcac 20

<210> 33  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>  
<223> G3PDH antisense primer

<400> 33  
tccaccaccc tggtgctgta 20

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**